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1 Introduction
1.1 Normal Hematopoiesis
Hematopoiesis is the process by which mature blood cells of
 distinct lineages are produced
from pluripotent hematopoietic stem cells (HSCs). Normal hematopoiesis depends on the
presence of normal pluripotent HSCs, a bone marrow microenvironment and a complex
system  of  highly  regulated  hematopoietic  growth  factors  with  overlapping  lineage
specificities (Smith 2003). The central feature of pluripotent HSCs is that they are capable of
both self-renewal and differentiation into mature hematopoietic cells (Weissman 2000).
Although single stem cells and their direct progeny may survive for long periods of time,
there may be a dynamic process by which some stem cells cease functioning and are replaced
by other stem cells that previously had been resting for a prolonged period of time in the G0
phase of the cell cycle (Hao, et al 1996). Regardless of the situation, the purpose of the stem
cells is accomplished, and normal individuals have stem cells that maintain hematopoiesis at a
stable level throughout their lifetimes (Domen and Weissman 1999).
1.1.1 Hematopoietic Stem Cells (HSCs)
HSCs are the common ancestor of all types of blood cells (Kondo, et al 2003, Weissman
2000). While HSCs are primarily found in the bone marrow (BM), they are present in a
variety of other tissues including peripheral blood (PB) and umbilical cord blood (CB), and
are found at low numbers in the liver, spleen, and perhaps many organs (Holyoake, et al 1999,
Mayani and Lansdorp 1998). Beginning with the groundbreaking experimental evidence, a
population of clonogenic bone marrow (BM) cells was found to generate myeloerythroid
colonies in the spleens of lethally irradiated hosts (McCulloch and Till 1960, Till and Mc
1961). These clonogenic cells in some cases gave rise to cells that also could be transferred to
secondary hosts and there reconstitute all blood cell lineages (Siminovitch, et al 1963). These
were
 proposed to be HSCs, or progenitor cells with the essential
 characteristic of self-renewal
and differentiation potential
 for all types of blood cells (Osawa, et al 1996).Introduction                                                                                                                            10
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However, it has been indicated that spleen colony forming unit cells (CFU-S) could only
achieve  transient  repopulation  (8-12  days)  of  irradiated  hosts  and  not  a  (long-term)
regeneration of functional tissue, an essential characteristic of true stem cells. (Harrison 1980,
Harrison and Astle 1997, Jones, et al 1989, van der Loo, et al 1994). The need for a practical
assay  that  allowed  the  specific  identification  of  primitive  HSCs  with  long-term
lymphomyeloid repopulating ability led to the development of competitive repopulation
assay, which provides a relative measure of “repopulating activity,” usually compared to a
reference standard of normal bone marrow cells (Harrison 1980, Harrison, et al 1978). The
development  of  clonal
 assays  for  all  major  hematopoietic  lineages  together  with  the
availability of multiparameter fluorescence-activated cell sorting
 (FACS) has enabled the
prospective purification of HSCs from
 mice and to highly enrich for HSCs from humans
according to
 the cell-surface expression of specific molecules and their
 functional read-out in
vivo and in vitro in stromal long-term
 colony-initiating assays (Baum, et al 1992).
HSCs can be divided into a long-term subset
 (LT-HSC), capable of indefinite self-renewal,
and a commit to differentiation pass through a phase of being short-term HSC (ST-HSC) that
self-renew for six to eight weeks, then advance to the multipotent progenitor (MPP) stage
(Christensen and Weissman 2001, Morrison and Weissman 1994).
Several  marker  combinations,  such  as  (Lin
neg/low,
 Thy1.1
low,  c-Kit
high,  Sca-1
+),  (Lin
-,
Thy1.1
low, Sca-1
+, rhodamine
 123
low) or (Lin
-, CD34
-/int, c-Kit
+, Sca-1
+), have been
 used to
isolate nearly pure mouse HSC populations. Similar marker
 combinations (Lin
-, Thy1
+,
CD34
+,  CD38
neg/low) (Morrison,  et  al  1995)  are  used
 to  highly  enrich  human  HSCs
populations. Although there are some
 variations in the exact frequencies found, the different
methods
 of isolation all indicate that HSC are rare cells. Using the
 (Lin
neg/low, Thy1.1
low, c-
Kit
high, Sca-1
+) markers approximately 1 in 5,000 mouse bone marrow cells has long-term,
multilineage, repopulating
 capability, i.e., is a LT-HSC, whereas approximately 1 in 1,000 has
a more limited,
 short-term, multilineage repopulating capability, i.e., is a
 ST-HSC  or  a
multipotent progenitor (MPP). Recently, the expression
 of the receptor tyrosine kinase Flk-2
has been identified as
 a reliable marker to discriminate between LT-HSC (Thy1.1
low,
 Flk-2
neg),
ST-HSC (Thy1.1
low, Flk-2
+), and MPP (Thy1.1
-, Flk-2
+)
 in combination with the (Lin
neg/low, c-Introduction                                                                                                                            11
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Kit
high,  and  Sca-1
+)
 markers.  Morphologically,  HSC  and  MPP  resemble  lymphocytes
(Christensen and Weissman 2001).
1.1.2 Early Lineage Hematopoietic Progenitor
MPPs self-renew for less than two weeks, but neither MPP nor ST-HSC are capable of
dedifferentiating to long-term HSC (LT-HSC) under any circumstances yet tested (Morrison,
et al 1997). These multipotent stem and/or progenitor cells then commit either to the myeloid
or lymphoid lineage by differentiating to common myeloid progenitors (CMP) or common
lymphoid progenitors (CLP) (Akashi, et al 2000, Hao, et al 2001).
Fig.1. Hematopoietic and Stem/progenitor Cell Lineages (Passegue, et al 2003). HSCs can be divided into LT-
HSCs with indefinite self-renewal or ST-HSCs with 6-8 weeks self-renewal. ST-HSCs differentiate into MPPs,
which do not or briefly self-renew, and have the ability to differentiate into oligolineage-restricted progenitors
that ultimately give rise to differentiated progeny. The CLPs give rise to T lymphocytes, B lymphocytes and
natural killer (NK) cells. The CMPs give rise to Granulocyte/macrophage progenitors (GMPs), which then
differentiate into monocytes/macrophages and granulocytes, and to megakaryotic/erythroid progenitors (MEPs),
which produce megakaryocyte/platelets and erythrocytes. Both CMPs and CLPs can give rise to dendritic cells.
All of these stem and progenitor populations are separable as pure populations by using cell surface markers.Introduction                                                                                                                            12
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Both CMPs and CLPs are clonal progenitors with little or no detectable self renewal capacity
and limited differentiation. Although the progenitors cannot durably engraft, they nonetheless
rescue lethally irradiated mice. CLPs give rise to progenitors of at least four classes of
cells—the T, B, and natural killer (NK) lymphocyte lineages, and antigen presenting dendritic
cells. CMPs give rise at least to granulocyte monocyte committed progenitors (GMPs) and
megakaryocyte erythrocyte progenitors (MEPs) (Fig.1) (Morrison, et al 1997, Shizuru, et al
2005). Granulocytes and monocytes differentiate in a bone marrow under the influence of
specific glucoproteins, so called colony stimulating factors (G-CSF, GM-CSF, M-CSF )
whose structure and mechanism of action is not yet fully understood (Lotem and Sachs 1982).
Besides them, there are several other growth and differentiation factors which play a role in a
normal hematopoiesis like erythropoietin, thrombopoietin, IL-1, IL-3, IL-5, IL-6 as well as
all-trans-retinoic acid (t-RA), which plays an important role in induction of the target genes in
differentiation towards macrophages (Brach and Herrmann 1991, Collins 2002). However, in
particular, t-RA delays the differentiation of primitive hematopoietic stem cells suggesting it
has an effect on HSCs according to their differentation status (Collins 2002, Purton, et al
2000).
1.1.3 Regulation of HSC Fate
During or after cell division, the two daughter cells
 of a stem cell have to decide their fate.
They can either
 choose to remain as HSC, commit to differentiation, or die
 by apoptosis.
Alternatively, they can also stay in the bone marrow or migrate
 to the periphery. These
processes are called HSC fate decisions and must
 be finely tuned to maintain a steady-state
level of functional
 HSCs in the bone marrow and to constantly provide progenitors
 for the
various hematopoietic lineages (Passegue, et al 2003). Expansion of HSCs by cell division
and exit of a fraction of HSCs from quiescent state occurs under both steady state and
conditions of mobilization.
The mechanisms that control whether a HSC self-renews or differentiates remain a mystery.
However, many of the important players in this regulation have been identified. The signalingIntroduction                                                                                                                            13
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pathways such as Wnt, hoxb4 genes, Notch1, Sonic
 hedgehog (Shh) pathways have emerged
as canditates for regulating self-renewal.
Besides transcriptional regulation and the stem cell niche that play a role in controlling stem
cell  fate,  HSCs  themselves  have  intrinsic  characteristics  or  clocks  such  as  the  cyclin
dependent kinase inhibitors (CDKI), which regulate the cell cycle with regard to the stage
and, in part, determine the number of cell divisions of HSCs (Krause 2002).
Although the global gene expression profiles for HSCs have been recently described, very
little is known about the dynamics of gene expression necessary for HSC fate decision. There
is evidence that early HSCs express a promiscous set of transcription factors and open
chromatin structure required to maintain their multipotentiality, which is progressively
quenched as these cells progress down a particular pathway of differentation (Akashi, et al
2003).
1.1.3.1 Wnt-signalling
Recent reports suggest that signaling through Wnt is a critical pathway utilized by LT-HSC in
self-renewing divisions. Contact of HSCs with Wnt results in signaling events such that HSC
enter the cell cycle with little differentiation out of the LT-HSC pool (Austin, et al 1997,
Reya, et al 2003, Shizuru, et al 2005, Willert, et al 2003). Wnt proteins are intercellular
signaling molecules that regulate development in several organisms  (Cadigan and Nusse
1997). Such a signal activates a pathway from the surface receptor “frizzled” (Fzd) via a gene
product called “dishevelled” (Dsh) to separate cytoplasmic β-catenin from a protein complex
(APC/axin/GSK3_). In its phosphorphylated form, β-catenin is held in the cytoplasm within
APC/axin/GSK3_/ β-catenin complex (Reya, et al 2001). The phosphorylation of β-catenin at
its NH2 terminus by GSK3_ targets it for ubiquitination and degradation by proteasomes.
GSK3_, one of the key components of the destruction complex, is known to be inhibited
through phosphorylation on Ser9 by activated Akt and other kinases (Doble and Woodgett
2003,  Jope  and  Johnson  2004)  thereby  coupling  these  kinases  with GSK3_-dependent
signalling  pathway.  When  Wnt  signals  through  Dsh,  the  complex  dissociates  andIntroduction                                                                                                                            14
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unphosphorylated, stabilized β-catenin is free to translocate to the nucleus, where it binds to
DNA binding proteins such as lymphoid enhancer factor (LEF) and T-cell factor (TCF),
converting them from repressors to activators of gene transcription . Activation of Wnt-
signalling in HSCs induces upregulation of genes such as hoxb4 and notch 1 (Reya, et al
2003), genes independently implicated in proliferation as well as self-renewal of HSC
(Antonchuk, et al 2001, Antonchuk, et al 2002, Karanu, et al 2000).
Fig.2. Wnt-signalling Pathway (Alberts, et al 2002). In the absence of Wnt-signalling (left panel), β-catenin is in
a complex with axin, APC and GSK3-β, and gets phosphorylated and targeted for degradation In the presence of
Wnt signalling (right panel), β-catenin is uncoupled from the degradation complex and translocates to the
nucleus, where its binds Lef/Tcf transcription factors, thus activating target genes.Introduction                                                                                                                            15
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1.1.3.2 Homebox B4; hoxb4 gene
The mammalian Hox homeobox gene family of transcription factors, consists of 39 members
arranged
 in 4 clusters (A, B, C, and D), which were initially described as important
 regulators
of pattern formation in a variety of embryonic tissues (van Oostveen, et al 1999). Several
homeobox transcription factors, such as HoxB3  and  HoxB4,  have  been  implicated  in
regulation of hematopoiesis. In support of this, recent studies indicate that overexpression of
HoxB4 strongly enhances hematopoietic stem cell regeneration. It was shown that long-term
repopulating activity of murine bone marrow cells was increased to at least 10-fold when
HoxB4 cDNA was over-expressed by retroviral infection in comparision to control stem cells
infected with empty vector (Bjornsson, et al 2003, Sauvageau, et al 1995).
The  potency  of  HoxB4  has  been  demonstrated  as  it  enabled  high-level  ex  vivo  HSC
expansion. Cultures of HoxB4-transduced HSCs achieved rapid, extensive, and highly
polyclonal HSCs expansions, resulting more than 1,000-fold higher HSC content relative to
controls. Besides, these HSCs retained full lympho-myeloid repopulating potential in mice
and did not lead to any hematologic abnormalities in the animals (Antonchuk, et al 2002).
Moreover, In another study, recombinant human TAT-HoxB4 protein carrying the protein
transduction domain of the HIV transactivating protein (TAT) has been reported to expand
hematopoietic stem cells by approximately 4- to 6-fold with normal in vivo differentiation
potential as well as long-term repopulation capacity (Krosl, et al 2003).
In addition, it has been shown that human long-term culture-initiating cells and nonobese
diabetic-severe combined immunodeficiency (NOD-SCID) mouse repopulating cells were
expanded by more than 20- and 2.5-fold, respectively, over their input numbers when they
were cultured on stromal cells genetically engineered to secrete HoxB4. Importantly, the
HOXB4-expanded HSCs enhanced stem cell repopulating capacity in vivo  as  well  as
maintenance of pluripotentiality. (Amsellem, et al 2003).Introduction                                                                                                                            16
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1.1.3.3 Notch1 Signalling
Members of the Notch gene family encode large transmembrane proteins, and four Notch
isoforms (Notch1_4) have been isolated from mammals (Robey 1997). Physiologic activation
of Notch
 signaling is initiated by binding of Notch ligands, such as Jagged1,
 Jagged2 and
Delta, that are also transmembrane proteins (Luo, et al  1997). Ligand
  binding leads to
proteolytic cleavage that results in the transport
 of the intracellular domain of Notch to the
nucleus, where Notch
 behaves as a transcriptional activator (Schroeter, et al 1998). A number
of studies support a broad physiologic role of Notch in the regulation of hematopoiesis.
Notch1 is expressed in bone
 marrow precursor cells as well as in peripheral blood T and
 B
lymphocytes, monocytes, and neutrophils, whereas Notch ligands
 are expressed in bone
marrow stromal cells, fetal liver, and thymus (Li, et al 1998). Notch activation promotes HSC
self-renewal, or at least the maintenance of multipotentiality (Karanu, et al 2000, Varnum-
Finney, et al 2000). A recent report has proposed a model in which Notch1 functions at
multiple levels in the hematopoietic cascade with distinct
 outcomes  dependent  on  the
differentiation stage at which it is
 activated. In the primitive populations, Notch1 facilitates
self-renewal of hematopoietic stem cells by impeding exit from
 the stem cell pool and
influences lineage outcome on a very primitive
 level, affecting the relative abundance of
lymphoid populations (Stier, et al 2002).
1.1.3.4 Sonic Hedgehog (Shh) Pathway
The vertebrate hedgehog family is represented by at least three members: Desert hedgehog
(Dhh), Indian hedgehog (Ihh) and Sonic hedgehog (Shh). All  encode  secreted  proteins
implicated in cell-cell interactions. Shh is the most extensively characterized vertebrate
member of this family and is involved in a wide variety of embryonic events (Johnson and
Tabin 1995).  Shh  and  its  receptors,  Ptc-1  and  Smo,  are  expressed  in  highly  purified
populations of primitive human blood cells, whereas, Dhh is found in schwann and sertoli cell
precursors and Ihh is expressed in gut and cartilage.Introduction                                                                                                                            17
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Addition of soluble Shh into HSC cultures results in an increase in the number of cells
capable of repopulating function. Conversely, cytokine-induced differentation was inhibited
by the addition of antibodies to hedgehog. These results indicate that Hedgehog proteins
regulate the expansion of hematopoietic stem cells. It turns out that Hedgehog signaling acts
upstream of bone morphogenetic protein-4 (BMP-4) to modulate BMP signaling and induce
proliferation without differentiation in primitive blood cells (Bhardwaj, et al 2001, Zon 2001).
Recently, the BMP signal has been shown to play a role in control of HSC number (Zhang, et
al 2003).
1.1.3.5 Stage Specific Cell Cycle Regulation in Early Hematopoiesis
Although quiescence is a defining characteristic of hematopoietic stem cells, expansion of
HSCs by cell division and exit of a fraction of them occurs under both steady state and
conditions of mobilization. Cyclin dependent kinase inhibitors (CDKI) are natural candidates
for proteins that oppose the cell cycle progression of HSCs. Just as there are several cyclin
dependent kinases, there are several CDK inhibitors (CDKIs) including p21
cip-1/waf-1 (p21),
p27
kip-1  (p27) and p18
INK4a.(p18). These CDKIs play distinct roles in the regulation of
hematopoietic self-renewal and differentiation. For example, p21 acts to maintain a stem cell
in a quiescent state of the cell cycle and limits the cell cycle entry of hematopoietic stem cells,
while p27 and p18 more specifically inhibit cycling of committed progenitor cells (Cheng, et
al  2000,  Steinman  2002).  On  the  other  hand,  p21  is  higly  expressed  in  replicating
hematopoietic progenitor cells (Furukawa, et al 2000, Steinman, et al 1998). This bicameral
role for p21, in which it restricts primitive cell cycling but promotes expansion of the
progenitor cell pool may reflect its ability to serve as an assembly factor for cyclin-dependent
complexes without inhibiting their activity (Cheng, et al 1999, Cheng, et al 2000, LaBaer, et
al 1997). Moreover, recent studies imply that p21 possesses differentiation stage-specific
effect in hematopoiesis (Stier, et al 2003).Introduction                                                                                                                            18
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1.1.3.6 Chromatin Modeling in Early Hematopoiesis
Local modeling of chromatin and dynamic changes in the nucleosomal
 packaging of DNA,
key steps in the transcriptional activation of genes, must occur to allow transcriptional
proteins
 contact  with  the  DNA  template  and consequently affect proper cell function,
differentiation and proliferation. Chromatin structure is an important factor in determining
whether a particular gene is expressed or not. All of the human genome is packaged into
chromatin, which is a dynamic macromolecular complex that consists of DNA, histones and
non-histone proteins (Wu and Grunstein 2000). The nucleosomes are the fundamental units of
chromatin structure, provide the first order and, at least in part, the higher-order packaging
and compaction of the DNA. The nucleosome core particle consists of 146 bp of DNA
wrapped around two molecules of each of the histones H2A, H2B, H3 and H4 (Luger and
Richmond 1998) (Fig.3).
Fig.3. Nucleosome. Each nucleosome consists of eight histone molecules (two each of histones H2A, H2B, H3,
and H4) associated with 146 nucleotide pairs of DNA and a stretch of linker DNA about 50 nucleotide pairs in
length. The diameter of the nucleosome "bead," or core particle, is about 10 nm. Histone H1 (not shown) is
thought to bind to the linker DNA and facilitate the packing of nucleosomes into 30-nm fibers. © 1999 by
Addison Wesley Longman.Introduction                                                                                                                            19
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The linker histone H1 stabilizies the higher order folding by electrostatic neutralization of the
linker DNA segment. In addition to their structural role, the histone proteins are also involved
in regulation of gene expression. As the maintenance of health depends on the coordinated
and tightly regulated expression of genetic information, this is a very important function of
histones. Post-translational modifications of histone tails, such as acetylation, phosphorylation
and methylation have emerged as common denominators in regulating several biological
functions (Berger 2001a, Berger 2001b, Iizuka and Smith 2003).
Posttranslational modification of histones by
 acetylation  is  one  of the best understood
mechanism by which cells regulate chromatin structure (Davie 1998, Kouzarides 1999).
Lysine residues in the N-terminal extensions of H2B, H3, and H4
 that exposed on the exterior
surface of nucleosomes are particularly
 accessible to acetylation. Acetylation of histones by
histone acetyl transferase (HAT) activity disrupts nucleosomes by confering negative charge
to the histone surface leading to breakage of the electrostatic attraction between histones and
DNA and allows the DNA
 to become accessible to the transcriptional machinery; conversely,
removal of
 the acetyl groups in other words, deacetylation by specific histone deacetylase
(HDAC)
 enzymes allows the histones to bind more tightly to
 DNA  and  to  maintain  a
transcriptionally repressed chromatin architecture. Both, HAT and HDAC activities can be
recruited to target genes in complexes with sequence specific transcription factors and their
coactivators or corepressors (Pazin and Kadonaga 1997, Redner, et al 1999).
In addition, HDAC activity is also an important component of epigenetic silencing by DNA
methylation (Robertson 2001). DNA can be methylated at the C5 position of the cytosine
within CpG dinucleotides, by the DNA methyl transferases DNMT1, DNMT3A, DNMT3B
These enzymes directly recruit HDACs, resulting in histone deacetylation and transcriptional
repression. Moreover, methylated CpG islands are bound by methyl –CpG-binding proteins
such as MeCP2, which can recruit HDACs and ATP-dependent chromatin modeling proteins
to form a tightly condensed chromatin structure (Flaus and Owen-Hughes 2001, Johnstone
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Fig.4. Cartoon Structure of Acetylation/Deacetylation of Histones (modified from Redner, et al 1999).
The random-coiled tails of the histone octamer represents the nucleosome with histones acetylated
(acetyl groups drawn as lollipop structures). The acetylated histone tails do not bind the DNA strands.
This allows the DNA to assume a more open configuration that is accessible to the transcriptional
machinery.
In addition, HDAC activity is also an important component of epigenetic silencing by DNA
methylation (Robertson 2001). DNA can be methylated at the C5 position of the cytosine
within CpG dinucleotides, by the DNA methyl transferases DNMT1, DNMT3A, DNMT3B
These enzymes directly recruit HDACs, resulting in histone deacetylation and transcriptional
repression. Moreover, methylated CpG islands are bound by methyl –CpG-binding proteins
such as MeCP2, which can recruit HDACs and ATP-dependent chromatin modeling proteins
to form a tightly condensed chromatin structure (Flaus and Owen-Hughes 2001, Johnstone
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Recently, it has been hypothesized that HSCs maintain a wide-open chromatin structure and
express a promiscous set of transcription factors to maintain their multipotentiality which is
progressively quenched as these cells progress down a particular pathway of differentation.
According to gene expression profiles from murine HSCs, both nonhematopoietic and
hematopoietic lineage-affiliated genes expressed at low level in HSCs and transcriptional
accessibility for lineage-affiliated program is progressively decreased, whereas genes related
to mature fuctions and structures become expressed as HSCs undergo differentiation (Akashi,
et al 2003).
These results suggests the concept that mechanism that govern HSC fate decision are likely
under  the  control  of  chromatin  modeling  programs  that  guide  at  least  transcriptional
accesssibility for each hematopoietic stage (Akashi, et al  2003). Recently, it has been
demonstrated that the combination of chromatin modeling agents such as trichostatin (TSA)
with  5aza  2’deoxycytidine  (5azaD)  which  lead  to  histone  acetylation  and  DNA
demethylation,  respectively,  resulted  in  expansion  of  HSCs  and  repopulation  of
immunodeficient mice (Milhem, et al 2004). In addition, valproic acid (VPA; a potent HDAC
inhibitor) has been reported to enhance the cytokine-induced expansion of HSCs at least in
vitro (De Felice, et al 2005).
In line with the important function of chromatin modeling in normal hematopoiesis according
to the recent studies, dysregulation of this dynamic process gives rise to transcriptional chaos
and  leukemic  transformation.  Dysregulation  of  chromatin  modeling  in  acute  myeloid
leukemias (AMLs) and novel therapeutic approaches through differentiation-inducing agent
like all-trans retinoic acid (t-RA), DNA methylation inhibitors and HDAC inhibitors will be
further disscussed in the section about leukemia.Introduction                                                                                                                            22
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1.2 Leukemia
Leukemias are a heterogeneous group of malignancies of hematopoietic cells. They are
monoclonal,  meaning  that  leukemic  phenotype  arises  as  a  consequence  of  malignant
transformation of a single cell. According to the progress of disease, they are classified as
chronic or acute; and with regard to the cell type affected as myeloid or lymphoid leukemias.
Although leukemias are heterogeneous in terms of phenotypes, there are general mechanisms
underlying leukemic transformation such as increased cell survival, proliferation capacity,
self-renewal capacity and impaired differentiation.
1.2.1 Chronic Leukemias
1.2.1.1 Chronic Myeloid Leukemia (CML)
Chronic myelogenous leukaemia (CML) results from the neoplastic transformation of a
haematopoietic stem cell. The initial chronic phase of this biphasic disease is characterized by
a  massive  expansion  of  the  granulocytic  cell  lineage,  even  though  most,  if  not  all,
haematopoietic lineages can be produced from the CML stem cell. The median duration of the
chronic phase is 3–4 years. Acquisition of additional genetic and/or epigenetic abnormalities
causes the progression of CML from chronic phase to blast phase. This phase is characterized
by a block of cell differentiation that results in the presence of 30% or more myeloid or
lymphoid blast cells in peripheral blood or bone marrow, or the presence of extramedullary
(spleen, liver or lymph nodes) infiltrates of blast cells (Ren 2005).
The cytogenetic hallmark of all phases of CML and a subset of cases of acute lymphoblastic
leukemia  (ALL)  is  a  t(9;22)(q34;q11)  translocation,  which  was  first  discovered  as  an
abnormal, small chromosome, named the ‘Philadelphia chromosome’(Kurzrock, et al 1988).
This translocation generates a bcr–abl fusion gene. Depending on the site of the breakpoint in
bcr, various different fusion proteins are produced: p185 (185 kDa), p210 (210 kDa), or rarely
p230. The p210 protein is seen in 95% of patients with CML and up to 20% of adult patients
with de novo ALL; the p185 form is seen in approximately 10% of patients with ALL and in
the majority of pediatric patients with Ph+ ALL (5% of all pediatric ALL cases). TheIntroduction                                                                                                                            23
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BCR–ABL fusion protein is required for the pathogenesis of CML, and the tyrosine-kinase
activity of ABL is essential for BCR–ABL mediated transformation (Deininger, et al 2000).
Allogeneic stem-cell transplantation is the only known curative therapy for CML. However,
most patients are not eligible for this therapy, because of advanced age or lack of a suitable
stem-cell donor. Imatinib mesylate (Glivec, previously known as STI571 and CGP 57148) , is
a rationally designed ABL specific tyrosine kinase inhibitor, has been shown to selectively
induce apoptosis of BCR–ABL+ cells, and is remarkably successful in treating patients with
CML except individuals with advanced phases (Druker 2002).
1.2.1.2 Chronic Lymphoblastic Leukemia (CLL)
Chronic lymphocytic leukemia (CLL) is a predominantly malignant clonal disorder of B
lymphocytes. Apoptosis dysregulation is a major feature of CLL, and while no clear pattern
has emerged, abnormal levels of Bcl-2 are common in CLL and Bcl-2 to Bax ratios are also
commonly disturbed (Keating 1999). Clinical studies have delineated factors that are helpful
in predicting prognosis and have provided data on promising new therapies for patients with
this disease, including stem cell transplantation, monoclonal antibodies, and gene therapy
(Wierda and Kipps 1999).
1.2.2 Acute Leukemias
Acute leukemias are characterized by the uncontrolled growth of the immature blood cell
precursors. When untreated, patients have a life span of several weeks or months, because
their normal blood cells become outnumbered by the leukemic ones (Hoelzer and Seipelt
1998).
It is important to distinguish between acute lymphoid (ALL) and acute myeloid leukemia
(AML) because of the different therapeutic approaches applicable to these two malignancies.Introduction                                                                                                                            24
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They can be distinguished based on a variety of morphologic, cytochemical and biochemical
features (Begemann et al., 1998).
1.2.2.1 Acute Lymphoblastic Leukemia (ALL)
ALL has its origin in a malignant transformation of a lymphoid precursor of either bone
marrow, thymus or other lymphoid tissue. ALL is an aggressive disease with a poor prognosis
which is further exacerbated by the presence of the Philadelphia chromosome (Ph+) — the
cytogenetic substrate of the t(9;22) — or by the t(4;11) (Hoelzer, et al 2002)
With the currently applied chemotherapy regimens survival ranges between 0-10%, even
though initial complete remission rates of 80% are comparable to those achieved in Ph
negative patients. Allogeneic stem cell transplantation is the only treatment with curative
potential, but treatment-related mortality and the relapse rate both remain high (Hoelzer and
Gokbuget 2000).
1.2.2.2 Acute Myeloid Leukemia (AML)
Acute myeloid leukemia (AML) is a clonal malignancy characterized by a block in myeloid
differentiation (Fialkow, et al 1987, McCulloch 1993). In the bone marrow and peripheral
blood, AML leads to accumulation of proliferating hematopoietic precursors, which are not
able to terminally differentiate and become functional blood cells. In this way space needed
for normal hematopoietic processes is occupied by leukemic blasts, in a process which will
finally be clinically manifested as leukemia (Hoelzer and Seipelt, 1998).
It is possible to distinguish between de novo, primary AML, and secondary AML which
arises as a consequence of either myelodysplastic syndrome (MDS), myeloproliferative
disease (MPD), treatment of neoplasia with cytotoxic substances such as alkylating agents (i.e
Cyclophosphamid), Topoisomerease II blocking agents (such as Etoposide, for the treatment
of ALL) or exposure to ionizing radiation (Pui, et al 1989, Scandura, et al 2002). There are
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are exposure to benzene and different genetic abnormalities among them trisomy 21 and
Fanconi’s anemia etc (Ferti, et al 1996).
In  1976,  a  group  of  hematologists  from  France,  America  and  England  founded  a
morphologically and cytochemically based classification of myeloid and lymphoid leukemias,
the FAB classification (Bennett, et al  1976).  According to this classification, myeloid
leukemias are divided according to the dominating cell type and its level of differentiation.
Figure 5: Morphology and differentiation level in AML
M1: Acute myeloblastic without maturation
M2: Acute myeloblastic with maturation
M3: Acute promyelocytic leukemia (APL)
M4: Acute myelomonocytic leukemia
M5: Acute monoblastic leukemia
M6: Acute erythroleukemia
M7: Acute megakaryoblastic leukemiaIntroduction                                                                                                                            26
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In addition to the FAB classification, specific chromosomal rearrangements/translocations
have been linked to distinct subtypes of acute myeloid leukemia or associated with particular
stages of disease progression or prognostic outcomes (Harris, et al 1999).
1.3 Molecular Pathogenesis of AML
1.3.1 Structural Themes
More than half of newly diagnosed cases of AML display detectable and usually single
cytogenetic abnormalities (Mrozek, et al 2001). The vast majority AML-associated genetic
aberrations are typified by balanced chromosomal translocations. Among the most common
gene rearrangements in AML are those involving the transcription factor complex Core
Binding Factor (CBF) and the nuclear hormone receptor retinoic acid receptor alpha (RAR_)
which account ~25% and ~10% of AML, respectively (He, et al 1999, Scandura, et al 2002).
Though less common then the CBF and RARα fusions, several other genes are recurrently
involved in leukemia associated translocations such as the MLL (Mixed Lineage Leukemia
gene) gene fusion which, though common in infant leukemias, occurs in less than 3% of adult
AMLs (Grimwade, et al 2001).
These structural rearrangements frequently involve the in-frame fusion of transcription factors
or regulators whose altered functions can interfere with regulatory cascades that have been
demonstrated to be critical for controlling the growth, differentiation and survival of normal
blood cell precursors (Look, 1997). This supports the widely held view that AML occurs
principally through transcriptional dysregulation. The abnormal regulation of transcriptional
networks occurs through common mechanisms that include alterations of specific subnuclear
compartments, dysregulation of chromatin modeling and recruitment of aberrant co-repressor
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1.3.1.1 CBF Leukemias (AML1 and CBFβ β β β)
CBF is a heterodimeric protein consisting of an AML1 subunit that directly contacts DNA (_
subunit), and a CBFβ subunit, which facilitates DNA binding. The normal functions of both
subunits are critical to hematopoietic development as mice lacking either gene fail to develop
definitive hematopoiesis (Okuda, et al 1996).
The heterodimeric complex activates transcription
 of  target  genes  involving  in  myeloid
differentation (i.e. IL-3, GM-CSF, M-CSF etc.) (Hiebert, et al 1996, Meyers, et al 1995).
Both AML1 and CBFβ genes are targets of chromosomal translocations in leukemia.
In one of the common translocation in AML, the N-terminal part of AML1 is fused to C-
terminal portion of ETO (eight twenty one) as a consequence of the t(8;21) translocation
found predominantly in the AML FAB subtype M2 (Miyoshi, et al 1991). ETO is a member
of a family of nuclear proteins which appears to be involved in the regulation of transcription
(Scandura, et al 2002). It interacts through coiled-coil regions (Minucci 2000) with N-CoR
(nuclear receptor corepressor) and recruits HDACs. (Gelmetti, et al 1998, Wang, et al 1998a).
Although the AML1/ETO fusion protein retains the ability to bind AML1-regulated target
sequences, it does not activate transcription, but instead dominantly represses AML1-
mediated activation (Lowenberg, et al 1999, Meyers, et al 1995). Transcriptional repression
appears to be mediated through the direct interaction of ETO with the nuclear corepressor and
recruitment of HDACs (Wang, et al 1998a) (Fig.6).
Moreover, AML1 has been found to be the target of the t(12;21) translocation in pediatric
ALL (Lowenberg, et al 1999). Here, almost the entire AML1 protein fused to the N-terminal
part of TEL, which acts as a transcription repressor (Chakrabarti and Nucifora 1999).
TEL/AML1 binds DNA via the runt homology domain (RHD) of AML1, redirecting the
repressor functions of TEL to AML1 targets. Similar to ETO, TEL directly binds corepressor
molecules and HDACs with its dimerization region and therefore represses AML1 target
genes (Fenrick, et al 1999, Romana, et al 1995).Introduction                                                                                                                            28
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Fig 6. AML1-ETO fusion protein (Redner, et al 1999). The association of the AML1 transcriptional activator
with a coactivator complex; indicates the binding of a corepressor to the AML-ETO fusion protein. NCOR:
nuclear receptor corepressor, HDAC: histone deacetylase, HAT: histone acetyl transferase, SIN3: Mammalian
SIN3 repressor protein.
The inv(16) and the t(16;16) mutations are mainly (but not only) seen in patients with FAB
subtype M4Eo AML. In these chromosomal rearrangements, the CBFß subunit of the core
binding-factor complex fuses to the smooth-muscle myosin heavy-chain (SMMHC) gene
MYH11 which is not known to play a role in normal hematopoiesis (Liu, et al 1993). In the
resulting in CBFß -MYH11 chimeric product, the N-terminal portion of CBFß, including its
AML1-interaction domain, is fused in-frame to a variable amount of the C-terminal domain of
MYH11 resulting in repression of AML1-mediated transcriptional activation either through
cryptic repressor domain of SMMHC portion of the fusion protein or by sequestering AML1
into functionally inactive complexes within the cytoplasm (Kanno, et al 1998).Introduction                                                                                                                            29
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1.3.1.2 APL
Nearly all cases of APL are associated with the t(15,17) translocation which results in a fusion
of RAR_ to the PML (promyelocytic leukemia) nuclear protein that localizes in distinct
matrix-associated structures known as nuclear bodies or PML oncogenic domains (PODs).
PML regulates senescence and apoptosis and functions as a growth suppressor (Dyck, et al
1994, Pandolfi 2001, Zhong, et al 2000).
The retinoic acid receptor (RAR) is a ligand dependent transcriptional regulator that is
important for myeloid differentiation. It forms heterodimers with retinoic X receptors (RXR)
which in the absence of the retinoic acid (RA) ligand interact with a large ubiquitous nuclear
protein (N-CoR). N-CoR mediates transcriptional repression through its interaction with other
proteins including mSin3A and HDAC (Heinzel, et al 1997, Horlein, et al 1995). The addition
of the retinoic acid ligand normally converts RAR-RXR from a transcriptional repressor to a
transcriptional activator (Collins 1998).
Fusion of PML to RAR_ results in enhanced interaction with the co-repressor complex N-
CoR, mSin3A and HDACs through PML coiled-coil regions by oligomerization (Minucci, et
al 2000). Only at pharmacological levels of ligand does PML/RAR
 release N-CoR, recruit a
coactivator complex, and allow histone
 acetylation and chromatin modeling to proceed. Thus,
for  PML/RAR -expressing
 APL  cells,  pharmacological  levels  of  RA  are  needed  for
differentiation-inducing therapy (Grignani, et al 1998, Lin, et al  1998). However, rare
variants of APL expressing the t(11;17) PLZF/RAR  fusion are not sensitive to RA–induced
differentation.  This  result  has  been  explained  by  demonstrating  that  PLZF  itself  is  a
transcriptional repressor that provides the fusion protein with a second binding domain for N-
CoR, mSin3A, HDAC co-repressor complex (Grignani, et al 1998, Ruthardt, et al 1997).
In addition to aberrant recruitment of HDAC complexes, it has been recently reported that
PML/RAR  fusion proteins can induce gene hypermethylation and silencing by aberrant
recruitment of DNA methyltranferases (DNMT1 and DNMT3a) to target promoters (i.e.
RARß2) in APL blasts, NB4 or U937 cells expressing PML/ RAR . (Di Croce, et al 2002,
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Fig 7. PML/RAR_ Fusion Protein in Acute Promyelocytic Leukemia (modified from Redner, et al 1999). (A)
The interactions of the RXR/RAR_ heterodimer with an N-CoR/Sin3/HDAC1 complex. Upon binding retinoid
acid, the RXR/RAR_ heterodimer releases the corepressor complex and binds a coactivator complex with
histone  acetylase  activity.  (B)  The  analogous  interactions  of  the  RXR/PML-RAR_  heterodimer  with  the
corepressor complex. Release of the corepressor complex occurs only in the presence of pharmacological levels
of retinoic acid. RXR: retinoic X receptors, RAR_: retinoic acid receptor alpha, N-CoR: nuclear receptor
corepressor, HDAC: histone deacetylase, HAT: histone acetyl transferase, SIN3: Mammalian SIN3 repressor
protein.Introduction                                                                                                                            31
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1.3.2 Functional Themes
1.3.2.1 Effect on Differentiation
A hallmark of AML is the aberrant differentiation with the accumulation of blasts resembling
a specific level of granulocytic maturation. Concerning the vast collection
 of AML-associated
fusion proteins, one of the two components
 of each fusion protein that directly interfere with
the hematopoietic differentiation program is generally a transcription factor (AML1,
 CBFß,
and RAR ). On the other hand, the other partner is more variable in function,
 but is often
involved in the control of cell survival and apoptosis
 such as the nuclear structure protein
PML. Moreover, AML-associated
 fusion proteins have been shown to affect hematopoietic
differentiation
  in  a  variety  of  experimental  models,  and  the  specific  stage
 of  myeloid
maturation arrest appears to be directly dependent on
 the nature of the fusion protein (Meyers,
et al 1995, Passegue, et al 2003, Scandura, et al 2002).
1.3.2.2 Effect on Apoptosis
The Bcl-2 family members,
 such as Bcl-2, Bcl-xl, Mcl-1, and A1, function as cell death
antagonists against a wide array of apoptotic stimuli, whereas
 their binding partners, like Bax,
Bad, and Bak, promote apoptosis
. The
 fusion protein AML1/ETO was shown to directly up-
regulate expression
 of Bcl-2 by binding to its promoter elements. Activation of the Bcl-2
promoter is the first demonstration of transcriptional activation by AML1/ETO, in contrast to
its previously identified repressor activity.
 In fact,
 cells from most human AML have been found to express Bcl-2 at
 much higher levels
than their normal counterparts (Passegue, et al 2003). A consistent story has emerged from
studies of the APL-associated fusion partners in transgenic mice (Pandolfi 2001). Within
nuclear bodies, PML colocalizes and physically interacts with P53 and Daxx, both mediators
of apoptotic stimuli. PML acts as a transcriptional coactivator of P53 and as such can
participate in the activation of P53 dependent apoptosis (Guo, et al 2000).  PML/RAR
disrupts nuclear body structure and is a dominant negative inhibitor of PML function, thus its
not surprising that hematopoietic progenitors from PML/RAR  transgenic mice are resistant
to  both  P53-dependent  apoptotic  stimuli  (Wang, et al  1998b). Similarly, Fas mediatedIntroduction                                                                                                                            32
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apoptosis is abrogated because the interaction between PML and Daxx is also disrupted
(Zhong, et al 2000).
1.3.2.3 Effect on Self-renewal
Acute myelogenous leukemia (AML) is typically a disease of stem/progenitor
 cell origin.
Interestingly,  the  leukemic  stem  cell  (LSC)  shares
 many  characteristics  with  normal
hematopoietic stem cells (HSCs)
 including the ability to self-renew and a predominantly G0
cell-cycle
 status (Bonnet and Dick 1997, Dick 2005, Guzman, et al 2002). Leukemic cells
absolutely require
 self-renewal capability to propagate the disease (Passegue, et al 2003). Wnt
signaling is an evolutionarily conserved signal transduction pathway that governs cell fate
decisions during embryogenesis and on the stem cell level. Wnt signaling has been implicated
in the self-renewal and proliferation of hematopoietic progenitor cells (Austin, et al 1997,
Reya 2003, Reya, et al 2003) .
Recently, the Wnt signaling pathway has been shown to be involved in human leukemia
development. _-catenin (plakoglobin) is closely related to β-catenin and is able to transform
cells, whereas β-catenin exhibits a transforming capacity only
 when  it  is  constitutively
stabilized by mutation. It has been demonstrated that the AML associated translocation
products  (AATPs)  PML/RAR , AML1/ETO,  PLZF/RAR   activate  Wnt  signaling  by
upregulating _ -catenin, which contributes to leukemogenesis by increasing the self-renewal
of early hematopoietic stem cells (Muller-Tidow, et al 2004, Zheng, et al 2004).
1.4 Novel Therapeutic Approaches in AML
Progress in acute myeloid leukemia conventional therapy and supportive care over the past
three
 decades has led to gradual improvement in the overall results,
 especially in adults up to
age 55-60. However, treatment outcome in elderly patients, which represent the vast majority
of AML, has remained disappointing despite intensive induction chemotherapy with complete
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In elderly patients, disease-free survival (DFS) typically is less than 10% at 3 years, with an
overall median survival of less than 12 month (Copplestone, et al 1989, Rowe, et al 2004). In
AML, different genetic alterations result in common patterns of deregulated gene expression,
leading to blockage of differentiation and favoring myeloid leukemogenesis. The limitations
and toxicity of conventional therapy aimed at killing the proliferating leukemic cells and the
underlying biology of AML have prompted the development of novel therapeutic concepts
based on the use of differentiation-inducing agents.
1.4.1 All-trans Retinoid acid (t-RA)
All-trans  Retinoid  acid  (tretinoin:  t-RA)  is  one  of  the  naturally  occurring  vitamin  A
derivatives (Miller 1998).  t-RA is a very potent promoter of growth and controller of
differentiation in many organ systems (Lotan, et al 1980), including hematopoiesis, by
inducing differentiation of promyelocytes into mature granulocytes in normal hemotopoiesis
(Douer and Koeffler 1982) as well as in acute premyelocytic leukemia expressing PML/RAR
fusion proteins (Huang, et al 1988). Therapy of APL with t-RA is well established. Combined
data published from Chinese, French, American and Japanese sources indicate a mean
complete  remission  response  of  85%  (Warrell, et al  1998).  When  this  remission  is
consolidated with chemotherapy, it leads to the long-term survival of APL patients in more
than 75% (Soignet, et al 1997). Although all other subtypes of AMLs express RARs, they are
not sensitive to retinoic acid action on differentiation (Fenaux and Degos 1997).
1.4.2 Demethylating Agents (DNA Methylation Inhibitors)
5-azacytidine  (5-Aza-C),  and  its  deoxy  version  5-aza-2'-deoxycytidine  (5-Aza-dC)  are
nucleoside analogues that inhibit DNA methyltransferases (DNMTs), which are involved in
methylating DNA, and lead to activation of silent genes, decondensation of chromatin,
differentiation in vitro (Maio, et al 2003) . PML-RAR -induced repression of RARß2 (RA
receptor) which is considered to be a putative tumor suppressor was only partially released by
either the DNA methylamine inhibitor 5-Aza-dC or the HDAC inhibitor trichostatin (TSA)
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RAR -induced  transcriptional  repression  and  differentiation  blockage  was  due  to  the
temporally recruitment of both histone deacetylases and DNA methyltranferases (Di Croce, et
al 2002). A synergistic effect of HDAC inhibitors and 5-Aza-C in restoring gene expression
has been observed both in hematological and non-hematological malignancies (Cameron, et al
1999, Klisovic, et al 2003).
1.4.3 HDAC Inhibitors (HDIs)
Various classes of compounds (hydroxamic acids, short-chain fatty acids, cyclic tetrapeptides,
cyclic depsipeptides and phenylene diamines) are known to be potent inhibitors of HDAC
activity (Johnstone, 2002). HDAC inhibitors prevent deacetylation resulting in a net increase
in acetylation of core histones, a release of chromatin folding thereby facilitating access of
transcription factors to DNA and activation of gene expression (Tse, et al 1998). As single
agents HDIs can induce a diverse array of leukemias to express differentiation characteristics
and  stop  proliferating.  Inhibition  of  the  cell  cycle  is  a  necessary  event  in  cellular
differentiation, and the cytostatic effects of HDIs are important for their anti-cancer activities.
Analysis of the cell cycle of tumour cells as well as in cell line models of acute leukemia that
have been treated with HDIs indicate that almost all HDAC inhibitors activate CKDI p21 and
the cells often arrest in G1, but sometimes accumulate in what seems to be the G2 phase of
the cycle (Gurvich, et al 2004, Kramer, et al 2001, Marks, et al 2000, Romanski, et al 2004).
Butyrates,  short-chain  fatty  acid-based  (SCFA)  substances,  were  the  first  HDIs  to  be
identified (Candido, 1978 cell) and successfully employed in experimental cancer therapy
(Gore and Carducci 2000). Unfortunately, butyrates require high concentrations in order to
achieve  inhibitory  effects  and  are  highly  unspecific.  Other  compounds  such  as  the
hydroxamic acid based HDI TSA, have more powerful and have higher inhibitor specifity
(Grunstein 1997, Marks, et al 2000).
APL has become the paradigm for the application of HDAC inhibitors. It has been shown that
either TSA or phenyl butyrate in combination with t-RA induce differentiation in some PML-
RAR  as well as PLZF-RAR - expressing APL cells that do not respond to RA alone. (Lin, et
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were reported to have a potential role in the treatment of AML1-ETO AML (Wang, et al
1999). Recently, Ferrara et al have shown that in AMLs, regardless of their underlying
genetic alteration, the retinoic acid signaling pathway is constitutively repressed through a
histone deacetylase (HDAC)-dependent mechanism and that inhibition of HDAC activities
restores the retinoic acid-differentiation response. These results indicate that repression of the
retinoic acid signaling pathway is a general pathogenetic event in AMLs and that HDACs are
common targets for AMLs, highlighting the possibility of transcriptional/differentiation
therapy also in AMLs other than APL (Ferrara, et al 2001).
1.4.3.1 Valproic Acid (VPA)
VPA  (2-propylpentanoic  acid)  is  a  short-chain  branched  fatty  acid  with  favorable
pharmacokinetic properties that has been used for decades in the treatment of epilepsy and
bipolar disorder (Johannessen 2000, Tunnicliff 1999). Recent data suggest that this drug, in
addition to its other known classical actions, can modulate the epigenome by inhibiting
histone deacetylases (HDACs) thus triggering an increase in gene expression. This inhibition
is most likely due to binding of VPA to the catalytic center of HDACs and thereby preventing
access to the physiological substrate, e.g. acetylated lysine residues in histone proteins
(Gottlicher, et al 2001, Gurvich, et al 2004).
It has been shown that VPA and its analogs inhibit multiple but not all HDACs with a
characteristic order of potency in vitro (Gurvich, et al 2004). Furthermore, VPA is the first
therapeutic agent to erase DNA methylation patterns in a replication-independent manner by
stimulating the accessibility of a demethylase enzyme (Detich, et al 2003).
Similar to more widely studied HDIs, VPA is under clinical evaluation due to its potent
differentiation effect on carcinoma cells, transformed hematopoietic progenitor cells and
leukemic blasts from AML patients (Gottlicher, et al 2001, Kuendgen, et al 2004). In a
previous clinical study (Bug et al., 2005b), the favorable effects of the combination treatment
with VPA/t-RA in patients with advanced acute myeloid
 leukemia were reported to result in
blast  cell  reduction  and  hypergranulocytosis  (>10
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Furthermore, it was possible
 to distinguish malignant from normal hematopoiesis in one
patient, by the presence
 of the isochromosome (17)(q10) in the leukemic blasts.
The  analysis
 revealed  that  whereas  the  CD34
+  progenitor  cells  contained  residual
isochromosome (17)(q10), all granulocytes had a normal karyotype, suggesting
 dominance of
normal hematopoiesis over the malignant clone most likely due to an enhancement of
nonleukemic myelopoiesis
  and the suppression of malignant hematopoiesis rather than
enforced
 differentiation of the leukemic blast. Recently, VPA has been reported to enhance
cytokine effect on the maintenance and expansion of HSCs at least in vitro consistent with the
hypothesis that VPA influences normal hematopoiesis (De Felice, et al 2005).
1.4.3.2 LAQ-824
The clinical candidate LAQ-824 is a hydroxamate-based HDAC inhibitor. In vitro, LAQ-824
inhibits HDAC enzyme activity with an IC 10 nM, inhibits and tumor cell growth at
submicromolar concentrations. Moreover, it induces apoptosis in several types of leukemia
including acute myeloid leukemia, acute lymphoblastic leukemia and chronic myeloid
leukemia cells. In addition, LAQ824 has significant activity in vivo, as demonstrated by its
ability to prolong the survival of mice injected with a myeloid leukemia cell line (Romanski,
et al 2004, Weisberg, et al 2004).
1.5 Purpose of the Study
Acute myeloid leukemia (AML) is a clonal malignancy characterized by a block in myeloid
differentiation. The rapid expansion of immature blasts in the
 bone marrow and the peripheral
blood progressively replaces the normal hematopoiesis, leading to evident hematopoietic
insufficiency. The vast majority of AML-patients are over 60 years
 old and experience a
median survival below 1 year even if treated
 with intensive chemotherapy (Rowe, et al 2004,
(Copplestone, et al 1989). It has been shown that the induction of the leukemic phenotype in
acute myeloid leukemia is strictly related to aberrant chromatin modeling, a major mechanism
of transcriptional control (Grignani, et al 1998, Minucci and Pelicci 1999) Therefore, the
profound toxicity, limited efficacy of current chemotherapy strategies and biology of AML
has prompted
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inducing
 therapy through histone deacetylase inhibitors (HDIs). HDIs
 have been shown to
promote differentiation regardless of the primary genetic lesion due to transcription regulation
by modification of chromatin structure either alone or in
 combination with differentiating
agents such as all-trans retinoic
 acid (Ferrara, et al 2001, Gottlicher, et al 2001).
The potent HDI valproic acid (VPA), safely used for over two decades in the therapy of
epilepsy and bipolar disorders (Johannessen 2000, Tunnicliff 1999) is now under clinical
evaluation  due  to  its  potent  differentiation  effect  on  carcinoma  cells,  transformed
hematopoietic progenitor cells and leukemic blasts from AML patients (Gottlicher, et al 2001,
Kuendgen, et al 2004). On the other hand, in a previous clinical study (Bug et al., 2005b),
favorable effects of the combination treatment with t-RA/VPA in patients with advanced
acute myeloid
 leukemia were reported most likely due to an enhancement of nonleukemic
myelopoiesis
 and  the  suppression  of  malignant  hematopoiesis  rather  than  enforced
differentiation of the leukemic blast. (Bug et al. 2005b).
Moreover, It has been recently hypothesized that an open chromatin structure is required for
HSCs multipotentiality and the lineage potential is hierarchically controlled during early
hematopoiesis most likely through the control of chromatin modeling program (Akashi, et al
2003). Consistent with this hypothesis, a combination of DNA demethylating agent and
trichostatin A (TSA) resulted in a significant expansion of primitive HSCs capable of
repopulating immunodeficient mice (De Felice, et al 2005, Milhem, et al 2004). Moreover,
VPA has been demonstrated to enhance early acting cytokine effect on the maintenance and
expansion of primitive human HSCs at least in vitro.
The aim of the present study was to investigate the effect of chromatin modeling through
VPA on HSC fate in order to evaluate the potential for clinical usage of HDIs in acute
myeloid leukemia (AML) therapy.Materials and Methods                                                                                                           38
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2 Materials
2.1 Instruments
Bacteria culture
Shaker inkubator (New Brunswick Scientific, Edison NJ, USA)
Petri, culture and cryotubes (Greiner, Heidelberg)
Centrifuges
Centrifuge 5415D (Eppendorf, Hamburg) and EBA12 (Hettich, Tuttlingen)
Centrifuge J2-MC with rotor JA 20 and JA 10 (Beckman Instruments, Munich)
Centrifuge Rotina 48 RS with rotor 4394 (Hettich, Tuttlingen)
Cool centrifuge Z320K (Hermle, Gosheim)
Megafuge 1.0 with rotor BS4402/A (Heraeus, Hanau)
Sorvall RC-5B refrigerated superspeed centrifuge and Biofuge 13R (Heraeus, Hanau)
Table centrifuge 5415C (Eppendorf Gerätebau, Hamburg)
Chemiluminescence Detection
Filme X-omat AR und BioMax (Eastman-Kodak, Rochester, USA)
FACS (Fluorescence-activated cell sorting)
FACScan (Beckton Dickinson, Heidelberg)
Gel electrophoresis system
DNA-subcell and Mini-Subcell System (Gibco, Betheseida, USA)
Geldryer modell 583 (BioRad, Munich)
Mini-PROTEN®II system and Power PAC 2000 (BioRad, Munich)
Irradiation of mice
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Magnetic cell separation (MACS)
„MiniMACS separation unit“, „MidiMACS separation unit“ and „MACS
multistand“(Miltenyni Biotech, Bergisch Gladbach)
Microscope
SZ40 Binocular (Olympus, Munich)
Inversed microscope (Zeiss, Oberkochen)
PCR
PCR-instrument and Thermal Cycler (Perkin Elmer Cetus, Norwalk, CT, USA)
Photos from CFU-S
Digital camera DSC- P72 (Sony, NJ, USA)
SZ40 Binocular (Olympus, Munich)
Spectrohotometry
DNA-Photometer GeneQuant (Pharmacia, Uppsala, Sweden)
Gene Quant II and Ultraspec® 2000 (Pharmacia Biotech, Freiburg)
Protein transfer cell
Trans-Blot® SD Semi-dry Transfercell (BioRad, Munich)
Real time PCR
ABI PRISM 7700 (PE Biosystem, Weiterstadt)
2.2 Chemicals
Acetic acid glacial, Borax, BrdU, bromphenol blue, BSA, CaCl2, coumaric acid, DEPC,
DMSO, EDTA, ethidiumbromide, eosin, Ficoll, glucose, glycerol, HEPES, H2O2,
isobutanol, methylen blue, NaH2PO4, Na2HPO4, NaN3, neutral buffered formalin,
Ponceau S, propedium iodide, SDS, TRIS, Triton X-100 und Tween20, xylencyanol
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Luminol (Fluka, Deisenhofen)
Ammonium persulphate, β-Mercapto ethyl alcohol, chloroform, ethyl acetate, isopropanol,
MgSO4, sodium acetate, sodium citrate, paraformaldehyde and phenole (Merck,
Darmstadt)
Ethanol, formaldehyde, glycine, HCL, potassium acetate, potassium chloride, methanol,
NaCl, Sodium deoxycholate, NaOH, phenol und X-Gal (Roth GmbH, Karlsruhe)
2.3 Antibodies
Primary
„Human CD34 progenitor cell isolation kit “ (Miltenyi Biotech, Bergisch Gladbach)
„Mouse lineage panel“ (Pharmingen, San Diego, CA, USA)
„Sca-1 multisort kit“ (Miltenyi Biotech, Bergisch Gladbach)
CD11b-Fluorescein-Isothiocyanat (FITC), CD14-Phycoerythrin (PE) and CD15-PE (Beckton 
Dickinson, Heidelberg)
CD33-FITC (Immunotech, Marseille, France)
Anti BrdU (FITC)-conjugated (Becton Dickinson, Heidelberg, Germany)
Anti- mouse CD45.2/Ly-5.2 FITC, anti-mouse CD45.1/Ly-5.1 PE congugated (Becton 
Dickinson, Heidelberg)
Monoclonal Rat IgG2a,κ Immunglobulin, Isotypkontrolle, R-Phycoerythrin conjugated,
Monoclonal Rat IgG2b,κ Immunglobulin, Isotypkontrolle, R-Phycoerythrin conjugated,
Monoclonal Rat anti-mouse Sca-1 IgG2a,κ Antibody, R-Phycoerythrin conjugated,
Monoclonal Rat anti-mouse c-Kit IgG2a,κ Antibody, R-Phycoerythrin conjugated
Monoclonal Rat anti-mouse Gr-1 IgG2b,κ Antibody, R-Phycoerythrin conjugated,
Monoclonal Rat anti-mouse Mac-1 IgG2b,κ Antibody, R-Phycoerythrin conjugated,
Monoclonal Rat anti-mouse CD45R/B220 IgG2a,κ Antibody, R-Phycoerythrin
  conjugated,
Monoclonal Hamster anti-mouse CD3ε IgG Gruppe 1, κ Antibody, R-Phycoerythrin
conjugated
Monoclonal Rat anti-mouse Ter-119 IgG2b,κ Antibody, R-Phycoerythrin conjugated
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Polyclonal rabbit-anti Akt IgG-Antibody, (α-Akt),
Polyclonal rabbit-anti Phospho-Akt (ser473) IgG-Antibody, (α-PAkt),
And -anti B-catenin IgG-Antibody, (α-B-catenin),
(all from Cell signalling, Beverly, MA, USA)
Monoclonal mouse-anti-B-tubulin antibody, (α-B-tubulin) (Merck, Darmstadt)
Monoclonal mouse-anti-GSK3B antibody, (α-GSK3B),
Monoclonal mouse-anti-Ser9-Phosho-GSK3B antibody, (α-P- GSK-3B) (both from Santa 
Cruz Biotechnology, Santa Cruz, CA, USA)
Monoclonal mouse-anti-HoxB4 antibody, (α-HoxB4), (University of Iowa, Iowa City, IA, 
USA).
Secondary
POD conjugated anti-rabbit, anti-mouse, and anti-goat IgG (Dako, Glostrup, Denmark)
2.4 Materials for Mouse Experiment
2.4.1 Mouse Strain
C57BL/6J (Ly5.2)
 and congenic C57BL/6.SJL-Ly5.1 female mice (Charles River, Sulzfeld).
2.4.2 Other Materials
Neo-Kodan (Schülke & Mayr, Norderstedt)
Forene (isoflurane) (Abbott GmbH, Wiesbaden)
Neomycin (Sigma, Deisenhofen)
27 GA _ Kanülen (Microlance 3) (Becton Dickinson, Franklin Lakes, NJ USA)
Titriplex III, 1,1% (Sigma, Deisenhofen)
Scalpel blade (Radiometer, Kopenhagen, Denmark)Materials and Methods                                                                                                           42
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2.5 Special Materials, Reagents and Cell Lines for Cell Culture
Special materials and reagents
DMEM- and RPMI-Medium, FCS, L-Glutamat, Penicillin/Streptomycin and Trypsin/EDTA, 
trypan blue (Gibco BRL, Paisley, Scotland)
X-VIVO 10 medium, (BioWhittaker, Verviers, Belgium)
9 % NaCl-solution(Braun, Melsungen)
Cell culture flasks, plates, cryotube TM vials (Nunc, Roskilde, Denmark)
MACS „LS-separation columns“, MACS „pre separation filter“ and „Sca-1 multisort kit“ 
(Miltenyi Biotech, Bergisch Gladbach)
0,2 and 0,45 µm inject filter (Millex-HA) (Millipore, Cork, Ireland)
„FACS Lysing solution“ (BD Biosciences, San José, CA, USA)
Methylcellulose-based
 semi-solid medium (Methocult GF M3434, Methocult GFH4434) 
(StemCell Technologies, Vancouver, BC, Canada)
70 µm and 40µm cell strainer filter (BD Labware, Franklin Lakes, NJ, and USA)
Cell lines
KG-1: human acute myeloid leukemia, established from the bone marrow of a 59-year-old
man with erythroleukemia that developed into acute myeloid leukemia (AML) in 1977
(Koeffler&Golde, Science 200: 1153-1154 (1978).
TF-1: human erythroleukemia, established from bone marrow of a 35-year-old man with
erythroleukemia in 1987 (Kitamura et al., Blood 73: 375-380 (1989).
Cell stimulators
All-trans retionic acid (t-RA) and Valproic acid (VPA) (Sigma, Deisenhofen), LAQ824 
(Novartis, Basel, Switzerland)
Cytokines
Murine IL-3 (Interleukin 3), murine IL-6 (Interleukin 6), murine SCF (stem cell factor) (Cell 
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Human IL-3 (10 ng/ml), TPO (20
 ng/ml), SCF, FL (50 ng/ml each), EPO (3 U/ml)
G-CSF,GM-CSF (R&D, Wiesbaden)
2.6 Materials for Molecular Biology
Microbiological Materials
Bacto-Trypton, yeast extrakt and Bacto-Agar (Biotest, Dreieich)
Gelatine, Maltose and milk powder (Difco, Detroit, MI, USA)
Ampicillin, kanamycin, streptomycin (Sigma, Deisenhofen)
Bacterial strain
E. coli – HB101: sup E44, hsd s20, (r
-
Bm
-
B)rec A13 ara-14, pro A2, lacY1, galK2, rps L20 
xyl-5mtl-1 (Invitrogen, Karlsruhe)
Vectors
pCDNA3 (CMV-Pro, lacP, lacZ, f1(-) ori, SV 40 ori, Neo, TK poly(A), Col E1 ori) 
(Stratagene, La Jolla, CA, USA)
pCR2.1 (lacZ’, Amp, Col E1, f1 ori, M13rev/T7-Pro) (Invitrogen, Karlsruhe)
Enzymes, Kits for Real Time PCR
Qiagen Plasmid Mini Preparations kit (Qiagen, Düsseldorf)
Superscript II RT
Platinium qPCR Supermix-UDG
Rox reference dye
„TA-Cloning-Kit“
(all from Stratagene, Mannheim)
Restrictions endonucleases (New England Biolabs, Frankfurt; Gibco BRL, Bethesda, NY, 
USA),
T4-Ligase and DNase I (Gibco BRL, Bethesda, NY, USA)
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3 Methods
3.1 Handling of Animals
C57BL/6J (Ly5.2) or congenic C57BL/6.SJL-5.1 female mice from
 8 to 12 weeks of age were
obtained from Charles River (Sulzfeld, Germany). Mice were bred at the stabulary of the
Clinic of J.W-Goethe University. All animals were housed (6 mice per cage) in specific
pathogen-free conditions and maintained on acidified drinking water (PH 3) or drinking water
with neomycin sulphate (1 mg/ml) for 7 d prior to and during the experiment for competitive
repopulating assay or colony formation unit spleen (CFU-S) assay experiments in order to
minimize radiation-induced mortality in lethally irradiated mice.
3.2 Enrichment of Human CD34
+ HSCs
Umbilical  cord  blood  (CB)  was  collected  immediately  after  delivery  in  a  sterile  tube
containing 5,000 I.E. heparin. Informed consent of the mother was obtained. Adult bone
marrow  (BM)  samples  were  obtained  from  healthy  volunteer  donors  (J.W.  Goethe
University). Mononuclear cells (MNC) were isolated from cord blood samples or adult bone
marrow by Ficoll/Hypaque centrifugation (2000 rpm, 20 min). Isolated MNC were washed
twice with MACS buffer (1100 rpm, 7 min). The CD34
+ selection was performed with the
Miltenyi Mini MACS column according to the manufacturer's instructions. Obtained MNC
were resuspended at a density of 1x10
8 cells in 300 µl MACS buffer containing a human IgG
to block the Fc receptors and an anti-CD34 antibody modified with a hapten and incubated for
15 min at 4 °C . Cells were washed with MACS buffer and incubated for another 15 min at 4
°C with an
 anti-hapten mouse monoclonal antibody conjugated to colloidal superparamagnetic
beads (Miltenyi Biotec).
After washing once with MACS buffer, labeled cells were
 applied to magnetic columns (MS
column, Miltenyi Biotec), unbound
 cells washed out, and CD34
+ cells eluted from the column
with
 MACS buffer. To improve the purity of the CD34
+ cells, a second
 purification cycle was
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3.3 Suspension Cultures of Human CD34
+ HSCs
5 x 10
3 CD34
+ cells/ml were seeded in 12-well-plates using X-VIVO 10 plus 1 % BSA and 1
% glutamine supplemented with recombinant human IL-3 (10 ng/ml), TPO (20 ng/ml), SCF,
and  FL  (50  ng/ml  each)  and  were  exposed  to  valproic  acid  (VPA)  with  increasing
concentration (30-150 µg/mL) for 7 d in liquid culture and incubated at 37 °C in humidified
atmosphere of 5 % CO2. Without medium exchange or cytokine readdition, cells were
harvested after 7 d counted and assayed for CD34 and CD14 expression by FACS.
3.4 Flow Cytometry of Human HSCs
For fluorescence-activated cell sorter (FACS) analysis, cultured CB and BM CD 34
+ cells for
10 d in methylcellulose and adult BM CD 34
+ for 7 d in liquid culture were collected and
washed twice with PBS containing 1 % FCS and 0.1 %
 NaN3 (1200 rpm, 5 min). 5 µl of
fluorescein
 isothiocyanate (FITC)-conjugated antibody were added, followed
 by incubation
for 15 min at 4 °C. After washing, the
 cells were fixed in 300 µl PBS with 2 % formaldehyde.
The
 antibodies were labeled as follows: FITC-conjugated CD34, CD14 for CD34
+ adult bone
marrow and CB cells. As negative control FITC-conjugated anti-huIgG1 was used.
 5000 to
10000 events were counted. Analysis was performed at a FACScan using CellQuest and PC-
Lysis
 software.
3.5 Colony Assay of Human HSCs
Cells were suspended at 5000 cells/ml on day 0 into 35-mm culture dishes containing semi-
solid methylcellulose medium supplemented with 30 %
 FBS, SCF (50 ng/mL), GM-CSF (10
ng/mL), IL-3 (10 ng/mL) and EPO (3 U/mL) (Methocult GFH4434, Stem Cell Technologies)
and were exposed to VPA with increasing concentrations (30-150 µg/mL) and incubated at 37
°C for 10 d in humidified atmosphere
 of 5 % CO2. Each assay was plated in triplicates. After
10 d
 of incubation, colonies were derived from methylcellulose, washed twice with PBS and
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3.6 Enrichment of Murine Sca1
+/lin
- HSCs
Sca1
+/lin
- HSCs were isolated from female C57BL/6J (Ly.5.2) or congenic C57BL/6.SJL-5.1
mice from
 8 to 12 weeks of age (Charles River). Mice were exposed to isoflouran 10-15 sec,
then sacrified
 by cervical dislocation. Before the separation of femora and tibiae from the
animal, legs area was sterilized by Neo-kodan. The femora and the tibiae were separeted and
all muscle tissue was removed from samples. BM was harvested from femora and tibiae by
flushing  the  bones  with  a  1  ml  syringe  and  26-gauge  needle  with  PBS  and  2  %
penicillin/streptomycin solution into 50 ml Falcon tube. Before mononuclear cell (MNC)
derivation, BM cells were passed through a 70 µm and 40 µm cell strainer filter, respectively.
BM cells were centrifuged at 2000 rpm for 20 minutes on Ficoll-Hypaque to obtain MNC.
Enriched MNC cells were washed twice with MACS buffer (phosphate-buffered
 saline (PBS)
containing  0.5  %  bovine  serum  albumin  (BSA)  0.1  %
 EDTA  (Titriplex  III,  Sigma,
Deisenhofen) and 1 % Penicillin/Streptomycin after Ficoll. Sca1
+/lin
- cells were purified by
immunomagnetic beads using the magnetic-activated cell separation (MACS) cell separation
columns (Miltenyi Biotec) according to
 the manufacturer's instruction.
For lineage depletion (lin
-cells), enriched and washed mononuclear cells were resuspended at
a density of 2 x 10
8 cells per ml in MACS buffer containing monoclonal antibodies specific
for murine T lymphocytes (CD3), B lymphocytes (B220), macrophages (Mac-1;
 CD11b),
granulocytes (Gr-1) and erythrocytes (TER-119) After 15 min of incubation at 4 °C, the cells
were washed (1000 rpm for 7 min), resuspended in MACS buffer at a concentration of 2 x 10
8
cells/ml together with streptavidin coatet MicroBeads (100 µl for 2 x 10
8 cells). After 15 min
of incubation at 4 °C, cells were centrifuged and labeled cells were removed by using
streptavidin-loaded
 MACS cell separation columns. Then selected and centrifuged Lin- cells
were stained with biotinylated anti-Ly6A/E (Sca-1, rat IgG2a, clone E31-161.7) following a
15 min incubation and centrifugation. Labeled cells were applied to magnetic columns (MS
column, Miltenyi Biotec) and unbound cells washed out. Sca1+ cells were eluted from the
column with
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3.7 Colony forming unit assays (CFU) and Replating efficiency of murine HSCs
After a 2 d stimulation in DMEM medium with 1 % P/S, 1 % glutamine, 10 %FCS mIL-3 (20
ng/mL),
 mIL-6 (20 ng/mL), and mSCF (100 ng/mL). Sca1
+/lin
- cells from Ly5.2 female mice
were  counted  and  plated  at  5000  cells/ml  into  35-mm  culture  dishes  containing
methylcellulose-based semi-solid medium (Methocult GF M3434, StemCell Technologies,
Vancouver, BC, Canada) and incubated at 37°C for 10 d in humidified atmosphere
 of 5 %
CO2 for colony formation assay. Each assay was plated in triplicates. On day 10 after plating,
the colony number was recorded and colony photos were taken under the microscope. After
washing  out  twice  with  PBS  from  methylcellulose,  cells  were  either  stained  for  the
determination of c-kit, Sca-1, Gr-1, and Mac-1 surface marker expression by fluorescence-
activated cell sorting analysis as explained before (FACS, Becton Dickinson) or plated again
(5000 cells/35-mm culture dish) in methylcellulose determining replating efficiency by serial
plating until the end of colony formation.
3.8 Day 12 spleen colony-forming unit assay (CFU-S D12 assay)
1000 Ly5.1 Sca1
+/lin
- cells were cultured in the presence of VPA alone or in combination
with t-RA (VPA: 150 µg/mL -/+ t-RA: 1 µmol/l) supplemented with DMEM medium, 1 %
P/S, 1 % glutamine, 10 %FCS mIL-3 (20 ng/mL),
 mIL-6 (20 ng/mL) and mSCF (100 ng/mL)
and incubated at 37°C for 2 d in humidified atmosphere
 of 5 % CO2. After 2 d, all cells that
grew from 1000 Ly5.1 Sca1
+/lin
- cells were washed twice with PBS (1200 rpm, 5 min.). Then
cells were resuspended in 150 µl PBS per mouse for all groups and injected retroorbitally
with a 1 mL syringe with a 25-gauge needle into lethally irradiated (10 Gy; 5 Gy for the
following 2 d) Ly 5.2 recepient mice (n=7). Moreover, one group was also included as a
control, consisting of 3 mice that received experimental treatment and radiation, but not
hematopoietic stem cells (nt: not transplanted mice). Mice were kept under sterile conditions
with 4 animals per cage and maintained drinking water with neomycin sulphate (1 mg/ml) for
1 week before and during the experiment. The cages were inspected daily. 12 d later,
transplanted animals were sacrified by cervical dislocation (a protocol approved by the local
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The spleens were removed through a left lateral incision and immediately fixed in Bouin's
fixative
 for 5 min, then transferred to 10 % neutral buffered formalin. The spleen colonies
were enumerated under the binocular microscope and the spleen colony pictures were taken
by digital camera (Sony, NJ, USA) after fixation. For fluorescence-activated cell sorter
(FACS) analysis of CFU-S assay, 3 spleen samples from different treatment groups (control,
t-RA, VPA) were passed through 40 µm cell strainer filters separately with 3 ml PBS and
washed once with PBS (1200 rpm, 5 min). Then spleen cells were resuspended in 100 µl PBS
and incubated with 1 µl of the phycoerythrin (PE)- conjugated monoclonal antibodies specific
for murine macrophages (Mac-1; CD11b), granulocytes (Gr-1) and stem cell marker (c-Kit,
Sca1) for 15 min at 4 °C. After washing with PBS once (1200 rpm, 5 min), the
 cells were
fixed in 300 µl PBS with 2 % formaldehyde. As negative control PE- conjugated anti-muIgG1
was used.
 5000 to 10000 events were counted. Analysis was performed
 at a FACScan using
CellQuest and PC-Lysis
 software.
3.9 Competitive Repopulation Assay
1000 Ly5.1 Sca1
+/lin
- cells were deposited into 96-well plates supplemented with DMEM
medium, 1 % P/S, 1 % glutamine, 10 % FCS mIL-3 (20 ng/mL), mIL-6 (20 ng/mL), and
mSCF (100 ng/mL) and incubated at 37 °C for 2 d in humidified atmosphere
 of 5 % CO2. All
cells that grew in culture under each culture condition were washed twice with PBS (1200
rpm, 5 min) and injected with a 1 ml syringe with a 25-gauge needle retroorbitally into
lethally irradiated (10 Gy) Ly5.2 female recipients mice of 8 to 12 weeks together with
 1 x
10
5 normal Ly5.2 bone marrow cells.
Mice (6 animals per cage) were kept under sterile conditions and maintained drinking water
with neomycin sulfate (1 mg/ml) 1 week before and during the experiment. The cages were
inspected daily. 12 weeks later, the femora and the tibiae were separeted and all muscle tissue
was removed from the samples. BM cells were harvested as explained before and stained with
conjugated monoclonal antibodies
 specific for Ly5.2 and Ly5.1 or mouse IgG2a (all from
PharMingen, San Diego, CA, USA) for 30 min at 4 °C for fluorescence-activated cell sorting
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3.10 Cell Cycle Analysis
5000 Sca1
+/lin
- cells were exposed to different histone deacetylase inhibitors (HDIs) alone or
in combination with t-RA(VPA: 150 µg/ml, Laq 824: 0,01 µmol/l -/+ t-RA: 1 µmol/l) in the
presence of DMEM medium,1 % P/S, 1 % glutamine, 10 %FCS mIL-3 (20 ng/ml),
 mIL-6 (20
ng/ml), and mSCF (100 ng/ml) and incubated in semi-solid medium at 37 °C for 7 d in
humidified atmosphere
 of 5 % CO2. After 7 d, cells washed in phosphate-buffered saline
(PBS), and fixed with 70 % ethanol at -20 °C.
Afterwards, cells were resuspended in PBS containing propidium iodide (PI; 50 µg/ml),
RNAse (5 µg/ml; Sigma) and incubated at 37 °C for 30 min and immediately
 evaluated by
FACS. For the bromodeoxyuridine (BrdU) incorporation, 2 x 10
6 cells were incubated with
10 µM BrdU (Sigma) at 37 °C for 25 min.
Cells were fixed by ice-cold 70 % ethanol, denatured by 4N HCL, stained with a fluorescein
isothiocyanate (FITC)-conjugated antibody against BrdU (Becton Dickinson, Heidelberg) and
with PI (5 µg/ml) and then analyzed by FACS
3.11 Cell culture
Cell culture of Eukaryotic cells was performed under sterile conditions (laminar air flow
hood). All plastic materials and solutions were autoclaved before usage (30 min at 121 °C ).
Cells were grown in culture flasks in a humidified atmosphere at 37 °C and by 5 % CO2.
TF-1 cells were cultivated in RPMI 1640 and supplemented with 10 % FBS, 2 mM L-
glutamine, 40  µg/ml  penicillin  and  40  µg/ml  streptomycin,  whereas  KG-1  cells  were
cultivated in X-VIVO 10 (BioWhittaker) supplemented with 1 % BSA
 and 1 % glutamine
(200 mM, GIBCO BRL). Cultures were maintained at 0.2-1.0 x 10
6 cells/ml; splitted 1:2 to
1:4 every 2-3 d and sowed out at about 1 x 10
6 cells/ml.
Cell number and viability were controlled by trypan blue exclusion. 40 µl cell suspension was
mixed with 10 µl of 0.4 % trypan blue in 0.9 % NaCl. Only unstained cells were considered
viable and their number was calculated as follows:Materials and Methods                                                                                                           50
50
Cell N
o [10
6/ml]= N
o of counted cells X dilution
 N
o of quadrants counted
Freezing:
For storing in liquid nitrogen, approximately 1 x 10
7 cells were collected at 1200 x g for 5
min and washed with PBS. After centrifugation, the cells were resuspended in 0.7 ml of
RPMI containing 20 % FCS, transferred into cryovials, and mixed with dropwise added 0.7
ml of RPMI containing 10 % DMSO. This suspension was immediately placed at –80 °C and
after 3-5 h stored in a liquid nitrogen tank.
Thawing:
Cryopreserved cells were taken out of liquid nitrogen, thawed rapidly in a 37 °C incubator
and resuspended in 5 ml of the culture medium. After one washing step (1200 x g, 5 min, RT)
to remove residual DMSO, cells were transferred into culture flasks and resuspended with
fresh medium.
3.12 Western Blotting
3.12.1 Lysis of Cells (Sambrook et al., 1989)
SDS lysis buffer:  0,1 % (w/v) SDS
1 % (w/v)Triton X-100
1 % (w/v) Sodium deoxycholat in 1xTBS
to 100 ml sterile water
Cells of each experiment group were washed twice with PBS (2000 x g for 10 min at 4 °C),
the supernatant was discarded and the cell pellet was resuspended with 60 °C hot lysis buffer
(100 µl per million cells) on ice. After 10 min of incubation on ice, lysates were exposed to
benzonase at RT for 5 min. After lysates were cleared, cells were vortexed and stored at -20
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3.12.2 Determination of Protein Concentration
Protein concentration was measured according to Bradford (1976) using commercially available
BioRad Kit. The standard curve was set by using 1:10 diluted BSA (0.05-0.4 mg/ml) and
protein samples compared to it by measuring the absorbance at λ=620 nm.
3.12.3 SDS-Polyacrylamide Gel Electrophoresis (SDS-PAGE)
SDS-PAGE electrophoresis (Laemmli, 1970) is used to separate proteins prior to their
analysis.
Sample buffer (2 X) 32 mM Tris-HCl pH6.8
10 % (v/v) glycerol
1 % (w/v) SDS
5 % (v/v) 2-mercaptoethanol
Running buffer 25 mM Tris
192 mM glycine
0.1 %(w/v) SDS
Mini Protean II® (8.5 cm X 6.5 cm) apparatus was assembled by using two glass plates and
side spacers. The resolving gel was mixed in acrylamide-bisacrylamide concentration that
matches protein weight (Sambrook et. al, 1989), and poured between  the  two  glasses.
Isobutanol saturated with ddH2O was laid over to ensure a flat surface and prevent from
trapping of air bubbles.
After the gel polimerization, isobutanol was washed out with water and stacking gel layed
over. When the stacking gel was polimerized, samples were prepared (80 µg of protein) with
sample buffer (25 µl of end volume), boiled for 3 min and loaded to the gel.
Since SDS denaturates proteins, their net migration through the gel is determined not by the
electrical charge but by molecular weight. Therefore stained protein standards (BioRad,
Novex) were always used for maching the positions of examined proteins.Materials and Methods                                                                                                           52
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The gel was run for 1 h at a constant voltage of 150 V. After electrophoresis, the gel was
stained with Comassie-blue (0.1 % Coomassie Brilliant Blue, 10 %(w/v) acetic acid, 30 %
(w/v) methanol) for visualising separated proteins.
3.12.4 Transfer of Proteins onto a Nitrocellulose Membrane (Western Blotting)
Following  the  gel  electrophoresis,  proteins  were  transferred  to  0.2  µm nitrocellulose
membranes (BioRad, Munich) in a process called Western blotting. This transfer was carried
out between two horizontal metal plates (Kyhse-Andersen, 1984) in a SemiDry System
(BioRad).
Transfer buffer 62.5 mM Tris-base, pH 7.4
20 % (v/v) methanol
The membrane was soaked in transfer buffer for 10 min, placed on top of the 3MM
Whatman® paper immersed in the same buffer and the gel was layed over. This was covered
by another sheet of wet 3MM Whatman® paper, all dimensions being slightly wider then the
gel. Transfer was carried out in excess of blotting buffer for 1 h by electric density of 0.3
mA/cm
2 and a 300-400 mA current.
Ponceau-S solution  5 g Ponceau-S was ressolved in 1 ml phosphoric acid and
ddH2O added to 100 ml.
Following Western blotting, membranes were usually stained with Ponceau-S for 5 minutes to
visualise protein bands. The ponceau was removed by washing with TBST, and membrane
stored by 4°C for further analysis.
3.12.5 Immunodetection of Specific Proteins
Proteins immobilized on a membrane were identified by using highly specific antibodies. The
membrane was first incubated in TBS-T containing 5% (w/v) Carnation milk in order to
saturate nonspecific protein binding sites, and after one hour (or overnight incubation by 4°C
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Primary antibody was diluted to appropriate concentration (1:200-1:10000) in a blocking
solution or TBS-T alone and membrane incubated for 3 hours to overnight.
Incubation was followed by three washing steps in TBS-T and secondary antibody added
(pig-anti-rabbit-couppled  to  POD  IgG,  1:2000,  or  as  recommended).  After  one  hour,
membrane was again repeatedly washed in TBS-T to remove unbound secondary antibody.
ECL I: 2.5mM  Luminol
0.4ml  p-coumaric acid (90mM in DMSO)
10mL  1M TrisHCl pH 8.5
to 100ml  with dd H2O
ECL II: 64µl  30% H2O
10ml  1M TrisHCl pH 8.5
to 100 ml  with dd H2O
Signals were detected in the dark by rinsing the membrane shortly in water and then
incubating with ECL (enhanced chemoluminescence system) I and II solutions in 1:1 ratio for
one minute.
Membranes were exposed to X-OMAT film for 30 to 5 min depending on the intensity of the
signal detected and antibody-bound proteins visualized.
Stripping buffer 62.5  mM  Tris-HCl, pH8.0
100  mM 2-mercaproethanol
2% (w/v) SDS
Blots were occasionaly stripped and reprobed with different antibodies. This was performed
by incubating the membrane in stripping buffer at 55°C for 1 hour, followed by extensive
washing in TBS-T. When 2-mercaptoethanol was no longer detectable, membrane was
covered with blocking solution and incubation procedures with primary and secondary
antibody repeated.Materials and Methods                                                                                                           54
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3.13 Quantitative Real Time Polymerase Chain Reaction RT-PCR
3.13.1 Isolation of Total RNA from Human Cells
During the isolation of the RNA from the eukaryotic cells CD34
+, TF-1cells, sterile and
disposable plasticware were used, all reagents prepared with DEPC-H2O, and several other
precautions were taken in order to prevent the activity of RNases. Isolation of RNA from the
eukaryotic cells were performed with the RNAeasykit (Qiagen according to the supplied
protocol. 1x10
6-3x10
8 cells were collected in a 50-ml falcon by centrifugation (1500 rpm, 10
minutes). The cells were washed twice with sterile PBS and supernatant removed. 350µl RLT
buffer (RNAeasykit, Qiagen, Hilden) together with B-mercaptoethanol were added directly to
the cells and vortexed. Then, 350µl fresh 70% EtOH (with DEPC-Wasser) were also added to
cells together with RLT+B-MET and carefully mixed. 700µl mixed solution were given to
seperation column and centrifuged at 10 000 rpm, 1min. After collection tube were emptied,
separation column were washed with 500 µl  RPE-buffer twice. Separation column was
transferred to eppendorf tubes centrifuged and dried. Following centrifugation, 30 µl DEPC
water were given to column. After incubation of 1 min, column were centrifuged at 10 000, 1
min and another 30 µl DEPC water was added to column. After centrifugation, dissolved
RNA in 60 µl DEPC were collected and stored at -80°C.
3.13.1.2 Quantitation of RNA
The concentration of RNA is determined by Agilent 2100 bioanalyzer. RNA samples were
thawed on ice and diluted 1/10 (100-400 ng/µl) with nuclease free water.1µl RNA dispensed
in to PCR tubes, denaturated at 70°C at least two minutes and was spinned. At the same time
RNA ladder aliquoted as 1µl in to nuclease free microcentrifuge tubes and heated at 70°C for
2 minutes. After RNA ladder is aliquoted and placed on ice, 9 µl gel-dye mixes loaded into
each of the well of the new chip. 5µl RNA 6000 Nano marker (Green), 1µl denaturated RNA
samples and 1µl denaturated RNA ladder were also pipetted into each well. The chip gently
placed on the vortex and vortexed for 1 minute. After vortexing, chip were placed receptacleMaterials and Methods                                                                                                           55
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and runned in the bioanalyzer. Individual electrograms were analyzed for quantitation and
quantification of RNA.
3.13.2 One Step Reverese-Transcriptase Polymerase Chain Reaction (RT-PCR)
After the measurement of the concentration of RNA by bioanalyzer, RT-PCR was performed
by Superscript one step RT-PCR (Invitrogen, Karlsruhe)
RT-PCR reaction mix:
25 µl 2x reaction buffer (a buffer containing 0.4 mM of each dNTP, 2.4 mM MgSO4)
1 µg RNA
0.5µM HoxB4fwd primer (2.5µl)
0.5 µM HoxB4rev primer (2.5µl)
1 µl RT/Taq mix (2x reaction buffer, 5mM and 50mM Magnesium Sulfate)
Ad 50µl with DEPC-H2O
Water control was also performed for RT-PCR reaction as the same reaction mix with the
exception of RNA. The reactions were set up on ice in 0.5ml PCR tubes, and PCR performed
in Thermal Cycler 480 (Perkin Elmer Biosystems, Weiterstadt). Following primer pairs were
used:
HOXB4 (corresponding to 1093-bp)
Human HOXB4 Fw: 5´-CCT GGA TGC GCA AAG AAG TTC A -3´
Human HOXB4 Rev: 5´-AAT TCC TTC TCC AGC TCC AAG A -3´
Invitrogen Life technologies,
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1.  cDNA synthesis: 50°C 30 min
2.  pre-denaturation : 94°C 2 min
3.  denaturation: 94 °C 45 sec
4.  anneal: 50 °C 45 sec
5.   extension: 72°C 45 sec
6.  final extension: 72°C 7 min
Reactions were controlled by gel electrophoresis (Agarose gel 2%).
3.13.3 Cloning of PCR product
3.13.3.1 Ligation
DNA fragments were ligated with linearized, dephosphorylated vectors in order to obtain
different plasmid constructs. This reaction was performed in presence of T4 DNA ligase,
which catalyzes formation of phosphodiester bonds between adjacent 3’-OH and 5’-P termini
of the DNA. Ligations were carried out as follow:
PCR- product 6µl
10* Ligation buffer 1µl
vector pCR2.1(3.9Kb) 2µl
T4 DNA ligase 1µl
Ligation samples were incubated at 16°C overnight.
(in a 20µl volume containing dephosphorilated vector, a two to threefold molar excess of
insert, 1µl of T4 DNA Ligase (400 U/µl, New England Biolabs) and 1µl of 10 X Ligation
buffer (50mM TrisHCl pH 7.6, 10mM MgCl2, 1mM DTT, 1mM ATP).Materials and Methods                                                                                                           57
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3.13.3.2 Transformation of Bacteria
Preparation of competent E.coli
Competent bacteria were prepared using CaCl2 method. Bacteria were streaked on petriplate
without amphicillin and incubated overnight at 37°C. A single colony of E.coli HB101 was
picked and inoculated in 5ml LB medium without ampicillin for overnight. After overnight
incubation,  the  miniculture  were  transferred  into  400ml  fresh  LB  medium  without
amphicillin, and grown at 37°C until reaching the OD600 (optical denstiy with a wavelenght of
600nm) of 0.5 - 0.6. Reading the optical density at 600 nm, at which wavelenght one OD unit
correspond to about 0.8x108 cells/ml, can monitor the growth of culture. When bacteria reach
the desired OD, the culture was immediately chilled on ice for 15 minutes and pelleted by
centrifugation at 4000 x g for 20 minutes at 4°C. The pellet was resuspended in 80ml of
sterile CaCl2 solution (50mM CaCl2, 10mM TrisHCl pH 7.4), by circular movements on ice
for 30 minutes. Cells collected by centrifugation at 4000 x g for 15 minutes at 4°C. Then,
11ml of CaCl2 and 2ml of glycerol solution were added to cell pellet which is then alliqouted
as 100µl in 1.5ml tubes and frozen immediately by immersing the tubes in liquid nitrogen and
stored at -80°C.
Transformation of Bacteria
Aliquot of competent E.coli bacteria was taken out of the liquid nitrogen, after 10 minutes
incubation on ice, 10µl ligation reaction were added and mixed by flicking the tube. Bacteria
were left on ice for the next 30 minutes and then exposed to the 42°C heat shock for 2
minutes. 500µl of LB (without antibiotic) were added, and samples incubated for 1 hour in a
shaking incubator.
Afterwards, bacteria were transferred onto the LB-ampicillin plates together with XGal, and
following  overnight  incubation  on  37°C,  individual  white  colonies  were  picked  for
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3.13.3.3 Miniprep: A Small Scale Preparation of Plasmid DNA
The preparation of plasmid DNA was performed by alkaline lysis method (Sambrook et al.,
1989).
Alkaline treatment causes proteins and linear chromosomal DNA of the host to denature
irreversibly.  The  denatured  chromosomal  DNA,  proteins  and  cellular  debris  are  then
precipitated with SDS at high concentrations of salt. For a small-scale preparation of plasmid
DNA, a 2ml culture of LB ampicilin medium (0.1mg/ml) was inoculated with a single
bacterial colony using a sterile toothpick. The culture was placed at 37°C in a shaking
incubator for 8 to 16 hours.
Resuspension solution (Sol I)  50mM glucose 
25mM  Tris-HCl pH 8.0
10mM EDTA pH 8.0
Alkaline lysis solution (Sol II) 0.2M  NaOH
1.1% (w/v) SDS
Neutralization solution (Sol III) 3M potassium acetate pH 5.2
1,5 ml of the overnight culture was spun at 14000 x g for 2 minutes, and the bacterial pellet
resuspended in 100µl of the solution (Sol I). The cells were lysed by addition of 200µl of the
alkaline lysis solution (Sol II) and mixed gently by inverting. Denatured chromosomal DNA
and cell debris were precipitated by addition of 150 µl of the ice-cold neutralization solution
(Sol III). The tube was inverted again, centrifuged (14000 x g, 5 minutes,  4°C),  and
supernatant extracted with mixture of phenol/chloroform. This mixture was used to separate
and remove proteins from preparations of nucleic acids. Phenol was equilibrated with Tris,
pH8.0 and chloroform used for DNA extraction was a 24:1 (v/v) mixture of chloroform and
isoamylalcohol (latter referred as sevag).
The DNA supernatant was then mixed with approximately the same volume of phenol/sevag,
briefly vortexed and spun (14000 x g, 2 minutes, RT), upper phase transferred in the new
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temperature and in presence of monovalent cations. One-tenth volume of 3M sodium acetate,
pH5.2, and 2,2 volumes of ice cold ethanol were added to each sample. DNA was precipitated
by incubation at -20°C for 3h to overnight, and followed by centrifugation at 14000 x g for 15
minutes at 4°C. The DNA pellet was rinsed with 70% (v/v) ethanol and finally dissolved in
50µl of dd water or 10mM TE buffer.
3.13.3.4 Determining of Nucleic Acid Concentration
A quartz cuvette was filled with dd H2O and photometer adjusted to zero. Preparation of
nucleic acids was strongly diluted (in dd H2O) and absorption spectrum of the solution
measured at a wavelength of 260nm. To determine the concentration of nucleic acids, a
following equation was used:
C=OD260nm x f x n,
Where C represents the concentration (µg/ml), OD equals optical density, f stands for dilution
factor and n was set by default as: 50µg/ml for DNA, 40µg/ml for RNA and 37 µg/ml for
oligonucleotids (all for 1 cm quartz cuvettes).
The ratio between the absorbance readings at 260nm and 280nm was used to estimate the
purity of nucleic acid preparation. Expected ratio of a very pure DNA or RNA preparation
was OD260/280 equals 1.8 or 2.0, respectively.
3.13.4 Standards for the Quantative Real Time PCR
After the measurement of the DNA concentration of the minipreprations, standards were
prepared from TF-1 cells according to the calculation below.
Calculation:
DNA(mol)= Mass (g)
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Molecular weight= DNA(mol) x 6,02x10
23
Dilution factor = Molecular weight(n/µl)
2x10
2(n-2)
Amount of stock sol= Desired volume
Dilution factor
Dilution:
10
n-2= amount stock sol.add 500 µl
10
n-3= 100 µl + 900 µl
.
.
.
10
1
3.13.5 cDNA Preparation
DNAase treated 10µgr total RNA that isolated from Human CD34
+ cells was combined in a
25µl final volume in the eppendorf tube together with DEPC-treated water. Then, heated at
70°C for 10 min and placed immediately on ice. Master mix were prepared and added into 25
µl RNA.
Mastermix:
Gibco 5x RT-buffer 10µl
DTT 5µl
PDN 0,25 µl
dNTPs 2µl
RNA-Guard 2µl
DEPC treated water 3,25µl
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RT reaction were performed in this conditions:
10 min 25°C
45 min 42°C
3 min 99°C
Then cDNA samples were stored in –20°C.
3.13.6 Taqman PCR
Human HOXB4 Fw: 5´-CCT GGA TGC GCA AAG AAG TTC A -3´
Human HOXB4 Rev: 5´-AAT TCC TTC TCC AGC TCC AAG A -3´
Human HOXB4 probe: 5´-FAM TGA GCA CGG TAA ACC CCA ATT ACG CC TAMRA3´
Human GAPDH Fw: 5'-CATCTTCCAGGAGCGAGA-3'
Human GAPDH Reverse Primer - 5'-TGTTGTCATACTTCTCAT-3'
Platinium qPCR Supermix-UDG (invitrogen)
Rox (invitrogen)
For the recommended reaction volume of 25µl for the Optical 96-Well Fast Plate, each PCR
reaction contains the components as listed as follows:
Supermix 12,5 µl
Primer 1(HoxB4, GAPDH) 0,5 µl
Primer 2 (HoxB4, GAPDH) 0,5 µl
Probe (HoxB4, GAPDH) 0,5 µl
DEPC water 8 µl
Rox 0,5 µl
cDNA/Standard 2,5 µlMaterials and Methods                                                                                                           62
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The TaqMan PCR was conducted
 in duplicates following standard protocols using the ABI
PRISM
 7700 (PE Biosystems). Normalization
 to glyceraldehyde-3-phosphate dehydrogenase
(GAPDH) was done
 for each sample.
3.13.7 Data Analysis
The Sequence Detector Software SDS 2.0 (Applied Biosystems)
 was used for data analysis.
The first step was to generate an
 amplification plot for every sample which shown ∆Rn on the
y axis (where Rn is the fluorescence emission intensity of the
 reporter dye normalized to a
passive reference and ∆Rn is the
 Rn of an unreacted sample minus the Rn value of the
reaction) against the cycle number, displayed on the x axis. From each
 amplification plot, a
threshold cycle (Ct) value was calculated, which is defined as the cycle at which a statistically
significant
 increase in ∆Rn is first detected and is displayed in the graph
 as the intercept point
of the amplification curve with the threshold. The threshold is automatically calculated by
SDS as the 10-fold
 SD of Rn in the first 15 cycles. The obtained Ct values were
 then exported
to a Microsoft Excel spreadsheet for further analysis.
The next step was to construct calibration curve plots, using
 Microsoft Excel as recommended
in User Bulletin 2 for the ABI
 Prism 7700 Sequence Detection System (Applied Biosystems),
showing
 Ct values on the y axis and the logarithm of the input amount
 of cDNA (equivalent to
the amount of total RNA) on the x axis. All human ABC transporters were subsequently
measured in the
 different human tissues, and the obtained Ct values were used
 to calculate the
initial input amount. Thereafter the results
 were normalized to the endogenous control,
GAPDH.
 In the last step, the expressions of each individual ABC transporter were compared
in the complete tissue panel. Therefore, for
 each ABC transporter, the normalized amount of
expression in
 the tissue that showed the lowest expression was used as a calibrator
 (set to 1),
and the remaining tissue samples were displayed
 as fold changes.Results                                                                                                                                   63
63
4 Results
4.1 Effect of VPA as A Single Agent on HSCs
The  potent  histone  deacetylase  inhibitor  (HDI)  valproic  acid  (VPA),  which  regulates
transcription through chromatin modeling like other HDIs, has been reported to induce
differentiation of carcinoma cells, transformed hematopoietic progenitor cells and leukemic
blasts from AML patients (Gottlicher, et al 2001). On the other hand, in a clinical study by
Bug et al, VPA/t-RA combination therapy in advanced AML patients resulted in blast cell
reduction and hypergranulocytosis. Importantly, it was possible
 to distinguish malignant from
normal hematopoiesis in one patient, by the presence
 of the isochromosome (17)(q10) in the
leukemic blasts. The analysis
 revealed that whereas the CD34
+ progenitor cells contained
residual  isochromosome
 (17)(q10), all granulocytes had a normal karyotype, suggesting
dominance  of  normal  hematopoiesis  over  the  malignant  clone  most  likely  due  to  an
enhancement of nonleukemic myelopoiesis
 and the suppression of malignant hematopoiesis
rather than enforced
 differentiation of the leukemic blast (Bug, et al 2005b). Moreover, VPA
has been recently demonstrated to enhance early acting cytokine effect on the maintenance
and expansion of primitive human HSCs at least in vitro consistent with the hypothesis that
VPA influences normal hematopoiesis.
Therefore, the effect of chromatin modeling through VPA on HSCs was investigated with
respect to differentiation, proliferation as well as self-renewal in the present study.Results                                                                                                                                   64
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4.1.1 VPA Increases the Proliferation of Human CD34
+ HSCs
In order to determine the effects of VPA on human HSC,
 the proliferation and differentiation
potential of human adult or umbilical cord blood CD34
+ cells were analyzed in the presence
both early cytokines and an external milieu that favors differentiation (supplemented by GM-
CF and FBS). Firstly, the effect of increasing doses VPA on adult CD34
+ cells were analysed
with respect to number of CD34
+ (stem cell marker) and CD14
+ (differentiation marker) cells
after 7 days in liquid culture in the presence of the early acting cytokines IL-3 (10 ng/ml),
TPO  (20
  ng/ml),  SCF,  and  FL  (50  ng/ml).  According  to  the  results,  VPA  prevented
differentiation
 of bone marrow CD34
+ cells in a dose-dependent manner as revealed
 by the
increase of CD34
+ cells and the concomitant decrease
 of  monocytic  CD14
+ cells upon
increasing doses of valproic acid in a 7-day liquid culture (Fig. 8A).
Figure 8. Proliferation and Differentiation of Human HSC on exposed to VPA. A, expression of CD34 and
CD14 in bone marrow CD34
+ on increasing concentrations of VPA (0, 30, 75, and 150 µg/mL). B, percentage of
CD34
+ cells in colonies of bone marrow CD34
+ plated in semisolid medium and cultured in the presence of FCS
and G-CSF for 10 days on increasing concentrations of VPA (0, 30, 75, and 150 µg/mL). C, total number of the
umbilical cord blood CD34
+ cells plated in semisolid medium and cultured in the presence of FCS and G-CSF
for 10 days on increasing concentrations of VPA (0, 30, 75, and 150 µg/mL).Results                                                                                                                                   65
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Secondly, the functional properties, proliferation and differentiation potential of HSC even in
the presence of high differentiation pressure supplemented by FBS and GM-CSF in the
semisolid medium were assayed by clonogenic CFU assay. The effect of increasing doses of
VPA on adult CD34
+ was analysed with respect to percentage of CD34
+ cells after 10 days in
methylcellulose. In spite of the higher differentiation pressure in a semisolid medium
supplemented with FBS and Granulocyte /macrophage colony-stimulating factor
 (GM-CSF),
150 µg/mL of VPA increased the percentage
 of CD34
+ cells from 0.5% to more than 21%
(Fig. 8B).
Lastly, the effect of increasing doses of VPA on umbilical cord blood CD34
+ cells, which
were more enriched in the early stem cell fraction (CD34
+/CD38
-) than BM cells ( De Felice,
et al 2005, Mayani and Lansdorp 1998) was analysed through CFU assay. Umbilical cord
blood CD34
+ cells harvested and analysed after 10 days
 of culture in semisolid medium with
respect to number of CD34
+ cells. VPA augmented the
 number of CD34
+ cells in a dose-
dependent manner more than
 1 log with respect to untreated cells (Fig. 8C).
These data clearly indicate that VPA does not induce
 differentiation, but proliferation in HSC.
4.1.2 Treatment with VPA Increases CFU and the Replating Efficiency
 of Murine HSCs
To compare the effect of VPA on HSC with
 the known enhancing effect of all-trans retinoic
acid (t-RA) on colony formation potential of murine HSCs (Collins 2002, Purton, et al 1999),
the investigation was extended
 to murine Sca1
+/lin
- HSCs. Thus, the effect of VPA (150
µg/mL) on the
 replating efficiency of Sca1
+/lin
- HSC was
 compared with that of t-RA (1
µmol/L) in the semisolid medium.
VPA did not only enhance
 the number of colony-forming units (CFU;Fig.9A) but also allowed
a second
 plating with a constant number of CFU, in contrast
 to that of t- RA which enhances
only replating efficiency (Fig.9A). VPA-treated
 cells did not differentiate as shown by the
high levels of the
 stem cell markers Sca1 and c-Kit (Fig.9B).Results                                                                                                                                   66
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Fig.9. Colony Formation of Sca
+/lin
-  HSC exposed to VPA or t-RA. A, replating efficiency of murine Sca
+/lin
-
HSC exposed to VPA (150 µg/mL). Reported are numbers of platings (I, II) and CFU. B, differentiation of
Sca
+/lin
- HSC on exposure to VPA (150 µg/mL) cultured in semisolid medium for 10 days; c-Kit as well as Sca1
were used as stem cell markers and Gr1 and Mac1 as myeloid differentiation markers.
In brief, VPA prevents murine HSCs from differentiation, increases proliferation as well as
replating potential of murine HSCs.
4.1.3 VPA Increases Self-renewal of the Murine HSCs
In order to figure out whether the effect of VPA on HSC in vitro is
 related to an increase of
their potential for self-renewal, the effect on VPA on the generation of CFU-S on day 12 from
cultured Sca
+/lin
- HSCs was investigated. Murine Sca
+/lin
- HSCs were treated for 2 days with
t-RA or with VPA and inoculated into lethally irradiated recipient mice. At day 12 the spleen
colony-forming units (CFU-S12) were analyzed. VPA -treated
 HSC gave origin to a higher
number of CFU-S D12 as compared with
 that of control and t-RA- treated HSC as revealed by
differences
 in the spleen size (Fig.10A). Exposure to VPA led
 to a higher percentage of c-Kit
and Sca1-expressing cells
 in the CFU-S D12 as compared with that of control (Fig.10B).Results                                                                                                                                   67
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Figure 10. CFU-S assay of Sca
+/lin
-  HSC  exposed  to  VPA  or  t-RA  for  2  days in vitro. nt-controls, not
transplanted recipients; control, untreated Sca
+/lin
- HSC; t-RA, t-RA treated Sca
+/lin
-  HSC;  valproic acid,
valproic acid treated Sca
+/lin
- HSC. Given is one of two experiments which yielded similar results. B, analysis of
surface marker expression in the CFU-S Sca
+/lin
-HSC exposed to VPA or t-RA. Sca1 and c-Kit: stem cell
Figure 10. A, CFU-S D12 Assay of Sca
+/lin
- HSC exposed to VPA or t-RA for 2 days in vitro. nt-controls, not
transplanted recipients; control, untreated Sca
+/lin
- HSC; t-RA, t-RA treated Sca
+/lin
-  HSC;  valproic acid,
valproic acid treated Sca
+/lin
- HSC. Shown are the spleens from one of two experiments which yielded similar
results. B, analysis of surface marker expression in the CFU-S Sca
+/lin
-HSC exposed to VPA or t-RA. Sca1 and
c-Kit: stem cell markers; Mac1 and Gr1: myeloid differentiation markers.Results                                                                                                                                   68
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CFU-S cells are far more differentiated than primitive HSCs and transient repopulation CFU-
S assay, which is limited to myeloid cell types, often fail to predict primitive function HSCs
that repopulate both the lymphoid and myeloid systems. Hence, the effect of VPA on the
more primitive ST-HSCs than CFU-S cells was examined through competitive repopulation
assay. Murine Ly5.1 Sca
+/lin
- HSCs were exposed to VPA or t-RA for 2 days in vitro. Then,
Untreated or VPA-, t-RA-treated Ly5.1 Sca
+/lin
- HSCs together with fresh normal Ly5.2 bone
marrow cells were inoculated into lethally irradiated Ly5.2 recipients and analyzed 12 weeks
after the transplantation. FACS analysis, using antibodies specific for the Ly5.2 (host) and
Figure 11. The effect of VPA and t-RA on Primitive Short-term Repopulating Hematopoietic Stem Cells (ST-
HSCs) of Sca
+/lin
- HSC exposed to valproic acid or t-RA for 2 days in vitro; Competitive Repopulation Assay:
donor cells are Ly5.1-positive cells in comparison with Ly5.2 recipient hematopoietic cells. Columns, mean (6
mice/group); bars, SD. Given is one experiment of two that yielded similar results.
Ly5.1 (donor) epitopes enabled the quantification of the percentage of residual host and donor
Ly5.2 (untreated) versus Ly5.1 donor (treated) cells in the mononuclear bone marrow cells.Results                                                                                                                                   69
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As compared
 with the untreated controls (8%), exposure to valproic acid
 increased the short-
term competitive repopulation potential (  4 months) of HSCs (18%) but to a lower
 extent
than t-RA (23%; Fig.11).
To sum up, VPA increase the number of CFU-S D12 and self-renewal or generation of
murine primitive ST-HSCs.
4.1.4 VPA Accelerates Cell Cycle Progression of hematopoietic
 stem cells and down-
regulates p21
cip-1/waf-1.
Following the proliferation and self-renewal analysis of murine HSC, a cell cycle analysis
was performed in order to investigate the effect of VPA on cell cycle progression of the
HSCs. The cell cycle analysis was assessed using Sca1
+/lin
- HSC cultured 7 days in semisolid
medium in the presence
 or absence of 150 µg/mL valproic acid. In contrast to
 t-RA, VPA
increased the percentage of the cells in
 S phase (23% and 38%, respectively) as compared
with that of untreated
 control cells (20%) with a concomitant reduction of cells in
 G1 phase
(Fig.12A).
To investigate the effect of VPA on cell cycle regulators in the hematopoietic cascade, the
expression
 of  the  cyclin-dependent  kinase  inhibitors  (CDKIs)  p21
cip-1/waf-1  (p21),  which
governs the entry of HSC into cell cycle and possesses a differentiation stage –specific
function in HSCs was examined. Murine Sca1
+/lin
-  HSC and human CD34
+ cells were
cultured in semisolid medium in the presence of VPA (150 µg/mL) for 7 days and for 2 days,
respectively and analysed for p21
 expression by western blotting.
In contrast to t-RA, VPA reduced the expression level
 of p21 in both human CD34
+ HSC (at
day 2) and murine Sca1
+/lin
- HSC even at day 7 (Fig. 12B,C).Results                                                                                                                                   70
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In conclusion, these data indicate that VPA accelerates
 cell  cycle  progression  of  HSC
accompanied by a down-regulation of
 p21.
Figure 12. Cell Cycle Progression of Sca
+/lin
- HSC exposed to VPA (150 µg/mL) and t-RA (1 µmol/L). A,
propidium iodide staining and BrdUrd incorporation of Sca
+/lin
¨ HSC on exposure to valproic acid (150 µg/mL)
and t-RA (1 µmol/L). The percentages of cells in G1, S, and G2-M are given in the respective gates. One
representative experiment of three is given. B, regulation of p21
cip-1/waf-1 in Sca
+/lin
- HSC on exposure to VPA
(150 µg/mL) and t-RA (1 µmol/L). Assessment of ß-tubulin was used as loading control. C, regulation of p21
cip-
1/waf-1 in CD34
+ HSC on exposure to valproic acid (150 µg/mL). ß-tubulin staining serves as loading control.Results                                                                                                                                   71
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4.1.5 VPA Inhibits GSK3ß and Up-regulates HoxB4 in HSCs.
One of the key components in Wnt signalling pathway is GSK3_ inhibition of which leads to
stabilization  of  ß-catenin  and  finally  self-renewal  of  HSC.  Recently,  VPA  has  been
demonstrated to exert an inhibitory activity on GSK3_ by phoshorylation on Ser9 and to
stimulate AKT in human neuoroblastoma cells (Su, et al 2004). To clarify the mechanisms
 by
which valproic acid induces proliferation and self-renewal of HSC, the effect of VPA on
GSK3ß expression and phoshorylation were investigated in both human and murine HSC as
well as human acute myeloid leukemia KG-1 cells through western blotting. KG-1 cells,
express the CD34 antigen characteristic of the hematopoietic stem cells, were cultured under
conditions (Xvivo10 medium) that about 80% of cell population were CD34+/CD38- (data
not shown).
Exposure to VPA induced a strong modification of GSK3ß
 in bone marrow CD34
+ cells at 48
hours (Fig. 13A) as well as
 in the murine Sca1
+/lin
- at day 7 (Fig. 13B).
 In fact, GSK3ß was
Ser9-phosphorylated in HSC on exposure
 to VPA but not to t-RA (Fig.13B) indicating an
inhibition
 of GSK3ß. This effect was also observed in KG-1 cells (Fig. 13C).
Owing to the fact that GSK3ß is known to be Ser9-phosphorylated by activated
 Akt (Jope and
Johnson 2004, Doble, et al 2003), the activation of Akt was also investigated in both HSC and
KG-1 cells. In CD34
+ , Akt was activated after 48 hours (Fig. 13D), whereas
 in Sca1
+/lin
- Akt
was not activated by VPA exposure at day 7 (Fig. 13E). This is most likely due to the late
time point of analysis as shown
 in KG-1 cells in which activated Akt returned to control levels
after 96 hours on exposure to VPA (Fig.13F)
Furthermore, Ser9-phosphorylated GSK3ß is known to stabilize ß-catenin and then lead to
self-renewal  of  HSC.
 After  it  has  been  shown  that  GSK3ß  is  inhibited  by  Ser-9
phosphorylation by exposure to VPA, the expression of ß-catenin was also examined by
western blotting. Given the fact that in both CD34
+ and Sca1
+/lin
- endogenous
 ß-catenin was
hardly detectable using a variety of
 antibodies (Fig. 13E. and data not shown), up-regulationResults                                                                                                                                   72
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of  ß-catenin  on  exposure  to  VPA  was  confirmed  in  KG-1
 cells,  which  are  >80%
CD34
+/CD38
- (Fig. 13F).
Figure 13. Regulation of Wnt-pathway components A, influence of VPA (150 µg/mL) on the expression as well
as the Ser9 phosphorylation of GSK3ß in CD34
+at 48 h; ß-tubulin: loading control. B, influence of VPA (150
µg/mL) on the expression as well as the Ser9 phosphorylation of GSK3ß in Sca
+/lin
-  HSC at day 7 of culture in
semisolid medium. ß-tubulin: loading control. C, influence of VPA (150 µg/mL) on the expression as
well as the Ser9 phosphorylation of GSK3ß in CD34
+/CD38
- KG-1 cells on exposure to VPA (150 µg/mL) at 48
h; Coomassie: loading control. D, influence of VPA (150 µg/mL) on the activation of Akt (direct proportion
between p-Akt and Akt) in CD34
+at 48 hours; ß-tubulin: loading control. E, influence of valproic acid (150
µg/mL) on the activation of Akt and on the expression level of ß-catenin in Sca
+/lin
- HSC at day 7 of culture in
semisolid medium; ß-tubulin: loading control. F, influence of VPA (150 µg/mL) on the activation of Akt and on
the expression level of ß-catenin in CD34
+/CD38
- KG-1 cells on exposure to VPA (150 µg/mL) at 48 hours; ß-
tubulin: loading control.Results                                                                                                                                   73
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HoxB4, a key factor in the regulation of the self-renewal and
 the proliferation of HSC, is one
of the target genes of ß-catenin
 (Reya, et al 2003). The expression level of HoxB4 in human
bone marrow CD34
+ cells was assessed by quantitative real-time PCR after 48 hours
 exposure
to VPA. VPA increased the number
 of HoxB4 transcripts about 3.8 times in these cells (Fig.
14A).
 In Sca1
+/lin
- murine HSC the expression level of HoxB4
 was measured by Western
blotting at day 7 of treatment. In contrast
 to t-RA, which seemed to reduce the amount of
HoxB4, valproic
 acid increased the expression of HoxB4 (Fig.14B).
Fig 14..HoxB4 Expression. A, induction of HoxB4 by VPA (150 µg/mL) in CD34
+ HSC in comparison with
untreated cells (Control) monitored by real-time PCR; number of copies defined by the comparison to a plasmid-
based standard curve. GAPDH expression was done as reference. The fold change between untreated controls
and VPA-treated cells is represented graphically. Representative experiment of three yielding similar results. B,
induction of HoxB4 by VPA (150 µg/mL) in Sca
+/lin
- HSC by Western blotting; ß-tubulin: loading controlResults                                                                                                                                   74
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These data indicate that VPA influences signaling
 pathways relevant for both self-renewal and
proliferation of
 HSC by the inhibition of GSK3ß and upregulation of HoxB4.
4.2 Effect of t-RA/VPA Combination Treatment on HSCs
All-trans retinoic acid (t-RA) is predominantly known for its differentiating effects, being a
potent inducer of terminal differentiation of malignant promyelocytes (Huang, et al 1988).
However, it has been also shown that t-RA has different effects on cultured hematopoietic
stem cells depending on their maturational state (Collins 2002, Purton, et al 1999). It was
indicated that t-RA enhanced the maintenance and/or generation of short-and long-term
repopulating cells from lin
- ckit
+ sca1
+ hematopoietic precursors (Purton, et al 2000).
It was observed that VPA as a single agent stimulates proliferation and self-renewal of HSC
(Bug, et al 2005a). In order to figure out whether the effect of VPA on murine HSC could be
further enhanced by the combination with t-RA, the effect of combination of t-RA/VPA (1
µmol/L, 150 µg/mL, respectively) on HSCs were
 compared with that of valproic acid (150
µg/mL) through colony forming unit potential with serial replating, colony forming unit
spleen assay (CFU-S) and competitive repopulating assay.
4.2.1 Treatment of VPA in Combination with t-RA further Increase Maintenance of
HSC up to the 6
th replating.
Murine sca1
+/lin
- HSCs were plated in methyl cellulose. Colony forming units were counted
and  colony  pictures  were  taken  at  day  10  after  plating,  cells  washed  out  from  the
methylcellulose for subsequent analysis of surface marker expression, and replated until the
end of the colony formation under the same conditions.
Combination of VPA with t-RA did not enhance the colony forming units as indicated by
colony counts in contrast to VPA, on the other hand, increased replating efficiency up to the
6
th cycle as opposed to other treatment groups (Fig.15 A). In other words, t-RA maintained the
incidence of HSCs until the 6
th replating in comparison to other treatment groups. t-RA
treatment  enabled  cells  to  give  colonies  up  to  4th  replating,  whereas,  VPA  treatmentResults                                                                                                                                   75
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maintained the colony formation for only up to the 3
rd replating in comparison to untreated
cells which did not give rise to any colonies after the 1
st replating.
Combination  of  VPA  with  t-RA  resulted  in  small  homogeneous  blast  colonies  of  the
progenitor cells similar to that of t-RA treated cells.
Fig.15 Colony Formation of Sca
+/lin
-  HSC exposed to combination of t-RA/VPA, valproic acid or t-RA. A,
Replating efficiency of murine Sca
+/lin
- HSC on exposure to t-RA/VPA (1 µmol/L /150 µg/mL, respectively).
Reported are numbers of platings (I, II, III, IV,V). B,colonie pictures of HSCs exposed to combination or as a
sinle agent t-RA, VPA from each passage.Results                                                                                                                                   76
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Fig 16. Differentiation of Sca
+/lin
- HSC upon exposure to t-RA/VPA (1 µmol/L //150 µg/mL) cultured in
semisolid medium for 10 days; c-Kit as well as Sca1 were used as stem cell markers and Gr1 and Mac1 as
myeloid differentiation markers.
To delineate the enhancement effect of replating efficiency up to the 6
th serial replating in
vitro,  murine  Sca1
+/lin
- HSC  treated  for  2  days  with  t-RA,  VPA,  or  t-RA/VPA  were
inoculated into lethally irradiated recipient mice.
At day 12 or week 12, the spleen colony-forming units (CFU-S) or competitive repopulation
efficiencies between VPA alone and combination of t-RA/VPA were compared. According to
the both transient and short-term competitive repopulation analyses, combination of t-
RA/VPA did not further enhance self-renewal of HSCs with respect to VPA as a single agent.
(data not shown).Results                                                                                                                                   77
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To sum up, combination of t-RA with VPA increase the replating efficiency up to the 6
th
replating meaning that maintains the HSCs at least in vitro up to 6
th replating, but does not
further enhance self-renewal potential of HSCs as indicated by repopulation analyses.
4.3 Comparison of LAQ824 and VPA effects on HSCs
LAQ-824, a hydroxamate-based HDAC inhibitor like TSA, has been shown to inhibit tumor
cell growth at submicromolar concentrations and induces apoptosis in several types of
leukemia including acute myeloid leukemia, acute lymphoblastic leukemia and chronic
myeloid leukemia cells (Romanski, et al 2004, Weisberg, et al 2004).
In order to confirm the data of VPA on HSC and to investigate whether other classes of HDIs
are also able to influence the fate of early HSCs, the effect of LAQ824 on HSCs was also
investigated and compared with VPA either alone or in combination with t-RA with respect to
proliferation and cell cycle progression.
4.3.1 LAQ824 Enhances CFU and Replating Efficiency of HSCs
To assess colony formation potential, 5000 murine Sca1
+/lin
- HSC were plated in methyl
cellulose. Colony forming units were counted and colony pictures were taken at day 10 after
plating, cells washed out from the methylcellulose for subsequent analysis of surface marker
expression, and replated until the end of the colony formation under the same conditions.
According to the CFU assay, LAQ824 did not only enhance the number of CFU but also
enables HSC to form colonies for the second passage similar to VPA. After the 2
nd passage,
both LAQ824- and VPA-treated HSCs failed to form colonies (Figure.17A) as shown by
colony count and pictures. Besides, addition of t-RA into LAQ824- treated HSCs enabled
cells to form colonies for one more cycle in comparison to LAQ824 alone. On the other hand,
the t-RA/LAQ824 combination did not maintain hematopoietic precursors in vitro after the 3
rd
replating in contrast to t-RA/VPA combination treatment, which further enhanced the
maintenance up to the 6
th replating.Results                                                                                                                                   78
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Fig. 17. Colony Formation of Sca
+/lin
-  HSC exposed to LAQ824 alone or a combination of t-RA/LAQ824. A,
replating efficiency of murine Sca
+/lin
- HSC on exposure to t-RA/LAQ824 (1 µmol/L /10 nmol/L)Reported are
numbers of platings (I, II, III, IV) from the CFU assay. B,colony pictures of HSCs exposed to LAQ824, t-RA
and VPA as a single agents or combinations.
In spite of the fact that LAQ824 and VPA showed a similar pattern for CFU number and
formation, the treated cells differed in the cell surface marker. LAQ824 treatment slightly
increased the percentage of c-kit and Mac1-expressing cells, whereas, VPA treatment highly
increased the percentage of Sca1 and c-kit –expressing cells with respect to untreated control
cells. Combination of LAQ824/t-RA treatment slightly decreased the percentage of c-kit
expressing cells, whereas increased Gr1-expressing cells with respect to LAQ824 treatment.Results                                                                                                                                   79
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Fig 18. Differentiation of Sca
+/lin
- HSC upon exposure to LAQ824 alone or t-RA/LAQ824 (1 µMol/L /10
nMol/L) cultured in semisolid medium for 10 days; c-Kit as well as Sca1 were used as stem cell markers and
Gr1 and Mac1 as myeloid differentiation markers.
These data suggest that LAQ824 enhances the proliferation and replating efficiency of HSC
similar to VPA. On the other hand, this effect might result from the effect of LAQ824 on
more mature HSCs with regard to HSCs targeted by VPA as shown by the different cell
surface marker expressing cells.
4.3.2 Effect of LAQ824 on Cell Cycle Progression of HSCs.
To further evaluate and compare the effect of LAQ824 on HSCs with that of VPA, cell cycle
progression of Sca1+lin- cells exposed to both LAQ824 and VPA was analysed after 2 days
in liquid culture in the presence of SCF, IL3 and IL6.Results                                                                                                                                   80
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Fig.19. Cell Cycle Progression of Sca
+/lin
-  HSC upon exposure to LAQ824 (10 nmol/L) or VPA(150 µg/mL)
exposure. Propidium iodide staining and BrdUrd incorporation of Sca
+/lin
- HSC on exposure to VPA (150
µg/mL) LAQ824 (10 nmol/L) .The percentages of cells in G1, S, and G2-M are given in the respective gates.
As shown in the Figure.19, lAQ824 like VPA increased the percentage of the cells in the S
phase of the cell cycle in comparison to untreated cells. There were no differences by the
addition of t-RA into both LAQ824 and VPA with respect to single VPA or LAQ824
treatment on cell cycle progression (data not shown). According to this data, LAQ824 seems
to trigger cell cycle progression of HSCs similar to VPA.
control VPA LAQ824
S-38%
G1-54% G2/M -9%
S-48%
G1-48% G2/M -5% G1-44% G2/M -2%
S-54%
control VPA LAQ824 control VPA LAQ824
S-38%
G1-54% G2/M -9%
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5 Discussion
A significant role of histone deacetylases (HDAC) in hematopoiesis is highlighted by findings
that aberrant chromatin modeling and interaction of acute myeloid leukaemia (AML)- fusions
with co-repressor/HDAC complexes plays a key role in the pathogenesis of AMLs (Grignani,
et  al  1998,  Minucci  and  Pelicci  1999).  Therefore, HDAC inhibitors (HDIs) received
considerable interest due to ability to promote differentiation and/or apoptosis in leukemic
blasts regardless of their primary genetic lesion, an effect achieved either alone or in
combination with differentiating agents, such as all-trans retinoic acid (t-RA) (Ferrara, et al
2001, Gottlicher, et al 2001).
VPA is one of the most promising HDI, raising the hope that a successful differentiation
therapy of AML might be possible according to recent studies. Contrary to recent opinion,
novel effects of VPA on hematopoietic stem cells (HSCs) were reported in the present study,
requesting reconsideration of the future role of VPA as well as other HDIs in AML therapy.
As opposed to recent report (Gottlicher, et al 2001) which shows that valproic acid
 induces
differentiation  and/or  apoptosis  of  carcinoma,  PML/RAR   transformed  hematopoietic
progenitor cells and leukemic blasts from AML patients , VPA blocks differentiation of
normal HSCs as revealed by the fact
 that it increases the fraction of HSCs rather than
differentiated
 cells. In other words, VPA does not induce
 differentiation, but proliferation in
HSCs in comparison to its effect on leukemic blasts. Furthermore, this novel effect is also
contrary to the effects of other HDIs which induce differentiation in leukemic blasts in vitro
and in vivo (Ferrara, et al 2001, Warell, et al 1998, Grignani, et al 1998, Minucci and Pelicci
1999)). In the study by Gottlicher et al, it has been reported that VPA has no toxic effect on
normal hematopoietic progenitor cells (lin- cells) as revealed by colony formation and
viability of the progenitor cells. On the other hand, the effect of VPA on primitive HSCs was
not further investigated.Discussion                                                                                                                             82
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The data observed in the present study compatible with the hypothesis that favorable effects
of the combination treatment with t-RA/VPA in patients with advanced acute myeloid
leukemia could result from an enhancement of nonleukemic myelopoiesis
 and the suppression
of malignant hematopoiesis rather than enforced
 differentiation of the leukemic blast.
Present result also consistent with the data indicates that VPA significantly enhances the
effect of early acting cytokines on the amplification of human HSC and selectively increases
the early human HSC compartment (De Felice, et al 2005). In the present study; however,
VPA increases the percentage and number of human HSCs not only in the presence early
acting cytokines, but also in the presence of the external milieu that favors differentiation.
These effects were confirmed in HSCs from BM and CB, which contains relatively higher
percentage of the early fraction (CD34
+/CD38
-) of HSCs with respect to BM. In another
study, the combination of HDI TSA with DNA hypomethylating agent 5AzaD in the presence
of cytokine cocktail favoring differentiation has been also reported to result in significant
retention of human stem cell phenotype and number. However, HSCs exposed to cytokines
and  to  either  TSA  alone  or  5AzaD  alone  had  a  more  limited  expansion  of  primitive
compartment of HSCs with regard to combination of TSA/5AzaD (Milhem, et al 2004). TSA
is a hydroxamic based HDI, which is functionally and structurally different from VPA.
Furthermore, VPA enhances CFU, percentage of stem cell markers-expressing cell and
replating efficiency with a constant number of CFU of murine HSCs with respect to t-RA
which only enhances replating efficiency, suggesting proliferation and self-renewal potential
of murine HSCs exposed to VPA. Moreover, addition of t-RA into VPA treatment shows a
synergistic effect on replating efficiency of HSCs, meaning the maintenance of HSC pool at
least in long-term culture conditions (Guel, et al 2003). Based on the recent reports, It is
known  that  t-RA  slows  proliferation  of  primitive  HSCs,  whereas  enhances  ex  vivo
maintenance/self-renewal of primitive hematopoietic stem cells (Collins 2002, Purton, et al
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Importantly, LAQ824, hydroxamic acid HDI, has been also demonstrated to have similar
effect of VPA on murine HSCs as demonstrated by an increase in both CFU and replating
efficiency. On the other hand, there are differences of the phenotype of HSCs between
LAQ824- and VPA- treated cells as well as decrease in the maintenance of HSCs exposed to
LAQ824/t-RA (unpublished data). These data suggest that these differences between VPA-
and LAQ824-treated HSCs might result from targeting different types of HSCs by these two
distinct types of HDIs. HSCs are heterogeneous and include long-term HSC, short-term HSC
and multipotent progenitors (MPP) which can be identified with respect to surface marker
expression and functional readout assays (Christensen and Weissman 2001, Morrison and
Weissman 1994). Thus, the difference observed between the distinct two distinct types of
HDIs might be further delineated by surface marker expression and functional stem cell
assays in vivo.
According though the present data, VPA is also confirmed to increase self-renewal of Murine
HSCs as shown by CFU-S D12 and competitive repopulation assay similar to t-RA (Collins
2002, Purton, et al 2000). Enhanced production of CFU-S D12 in the VPA-treated cultures
suggests  that  VPA  enhances transient  repopulating  ability  due  to  the  direct  effect  on
hematopoietic progenitor cells or more primitive short-term repopulating cells (ST-HSC)
which could also result in enhanced CFU-S production but can not be detected by CFU-S
(Harrison 1980, Harrison, et al 1978, Purton, et al 2000, van der Loo, et al 1994). According
to the short-term competitive repopulation analysis (  4 months), functional assay of more
primitive  cells  (ST-HSCs)  than  CFU-S,  VPA  increases  the  short-term  competitive
repopulation of HSCs similar to t-RA, suggesting the self-renewal of primitive HSCs.
However, this effect of VPA on the ST-HSCs could even result from self-renewal of the most
primitive long-term HSCs (LT-HSCs). These possibilities could be distinguished
 by long-term
competitive reconstitution analysis (  6 months) which would be the topic of the further
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Conversely, combination of t-RA/VPA did not give any additive or synergistic effect on the
self-renewal of HSCs. But, combination of t-RA/VPA most probably maintains primitive
HSC pool like t-RA (Collins 2002) rather than expands in comparison to VPA according to in
vitro results obtained by CFU serial replating and phenotype analysis in this study. This
synergistic effect of t-RA/VPA on replating efficiency meaning maintenance of HSC in vitro
might be further delineated by serial CFU-S or competitive repopulating assay as short- and
long term maintenance in vivo, which may be also the one topic of further research.
An asymmetrical induction of apoptosis in the
 HSC population by valproic acid was excluded
by the evidence
 that valproic acid accelerates the cycle progression of HSC
 accompanied by a
down-regulation of p21
cip-1/waf-1. However, this effect is
 in contrast to the effect of valproic
acid as well as other HDIs which increase p21
cip-1/waf-1 expression in cell
 line models of acute
leukemia followed by differentiation or
 apoptosis (Gurvich, et al 2004, Romanski, et al 2004).
Therefore, Valproic acid affects normal hematopoietic stem cells (HSC) in a manner that is
distinctly different from that exerted on leukemic blast cells. There
 is a direct relationship
between the differentiation status and the
 response to HDIs, meaning that very immature cells
respond to
 HDI with a down-regulation of p21
cip-1/waf-1 and cell cycle progression, whereas at a
more advanced differentiation stage,
 cells respond to valproic acid with a up-regulation
 of
p21
cip-1/waf-1 and differentiation or apoptosis. p21
cip-1/waf-1 is one of the cyclin-dependent kinase
inibitor (CDKI) which plays critical roles in the regulation of cell cycle kinetics in the
hematopoietic  cascade  and  governs  the  entry  of  HSC  into  cell  cycle  and  possesses
differentiation stage –specific function in HSCs (Cheng, et al 1999, Cheng, et al 2000,
LaBaer, et al 1997, Stier, et al 2003). Furthermore, another potent HDI LAQ824 seems to
accelerate cell cycle progression similar to VPA (unpublished data). Yet, further studies
should be conducted before the last statement about the effect of LAQ824 on HSCs.
It could be hypothesized that VPA increases self-renewal
 of HSCs by the inhibition of
GSK3 β or "transcriptional reprogramming " of these cells through chromatin modeling. But,
it is most likely that both of these mechanisms are involved in VPA-induced self-renewal of
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One of the mechanism by which valporic acid increases self-renewal
 of  HSC  might  be
explained by the inhibition of GSK3β, which is the negative regulator of the Wnt-signalling
pathway.
In the present study, VPA has been demonstrated to inhibit GSKβ by phosphorylation on Ser9
as claimed previously (Su, et al 2004) Furthermore, GSK3β is phosphorylated by activated
Akt as shown both in CD34
+ and acute myeloid leukemia (AML) cell line KG1 cells that are
>80% CD34
+/CD38
-. On the other hand, Akt was not activated by VPA exposure in Sca1
+/lin
-
most likely due to the later time point of analysis in this cells with respect to KG-1 as well as
CD34
+ cells. Akt has been demonstrated to return baseline levels after 96 hrs in VPA-treated
KG1  cells.  According  to  the  recent  studies,  GSK3_ is known to be inhibited through
phosphorylation on Ser9 by activated Akt (Doble and Woodgett 2003, Jope and Johnson
2004). Moreover, up-regulation
 of β-catenin on exposure to VPA was confirmed in KG-1
cells. It is known mechanism that The Ser9 phosphorylation of GSK3β reduces its kinase
activity on β-catenin enabling it to transcriptionally activate Wnt target genes.
The  activation  of  the  Wnt-signaling  pathway  by  valporic  acid  is  also  confirmed  as
demonstrated by the up-regulation of Wnt-target gene as well as transcription factor, HoxB4.
Evidences suggest that Wnt-signalling pathway is a critical pathway utilized by LT-HSC in
self-renewing divisions. (Austin, et al 1997, Reya, et al 2003, Shizuru, et al 2005, Willert, et
al 2003) Activation of Wnt signalling results in signaling events such that HSC enter the cell
cycle with little differentiation out of the LT-HSC pool (Reya et al 2003). Furthermore,
activation of Wnt-signalling in HSCs induces upregulation of genes such as hoxb4 (Reya
2003), genes independently implicated in proliferation as well as self- renewal of HSC
(Antonchuk et al., 2001&2002, Amsellem, et al 2003, Krosl, et al 2003)
In fact, in the present study, VPA increases self-renewal of murine HSCs as shown in both
CFU-S as and competitive repopulation assays, suggesting its self-renewal effect on primitive
HSCs similar to t-RA (Purton et al., 2000). However, one should be careful in comparing the
result of the studies on humans and on mice. Therefore, investigation of the effect of VPA onDiscussion                                                                                                                             86
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self-renewal and/or engraftment potential of human primitive HSCs using NOD-SCID mice
might be useful.
Another  mechanism  involved  in  VPA  induced  self-renewal  of  HSCs  might  be  a
„transcriptional reprogramming" of these cells
 through chromatin modelling. VPA is known
to induce histone acetylation as well as
 DNA demethylation in a dose-dependent manner
(Gottlicher, et al 2001, Detich et al., 2000). In addition to its potent and specific inhibition of
HDAC, VPA is the first therapeutic agent shown to erase DNA methylation patterns in a
replication-independent manner by stimulating the accessibility for a demethylase enzyme.
(Detich, et al 2003).
Modification of chromatin structure is an important factor in determining whether a particular
gene is expressed or not. Histone acetylation by HAT is associated with the activation of
genomic regions, whereas deacetylation of histone leads to a chromatin conformation
resulting in gene silencing. In addition, DNA methylation is associated with the silencing of
gene expression through DNA methyl transferases.
Therefore,  actual  HSC  fate  decisions  may  be  governed  by  the  expression  patterns  of
transcription factors such as HoxB4 and may be under the control of methylation and
deacetylation of chromatin, while commitment or differentation might be triggered and
regulated through external regulatory pathways, activated by interactions of HSCs with
cytokines or the marrow microenvironment.
The data presented here suggest that VPA can act as transcriptional regulator through
chromatin modeling due to its capacity to induce histone acetylation and active DNA
demethylation in the self-renewal of primitive HSCs and commitment of more mature
progenitor cells into different lineages. Furthermore, it seems that VPA treatment resulted in
interruption of the ongoing differentiation process driven by external factors such as cytokines
and reprogramming of HSCs fate decision.Discussion                                                                                                                             87
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During the course of this study another group has reported that human bone marrow CD34
+
cells exposed in combination with DNA demethylating agent (5aza 2’deoxycytidine, 5azaD)
and HDAC inhibitor trichostatin A (TSA) resulted in a significant expansion of primitive
HSCs capable of repopulating immunodeficient mice even in the presence of cytokines that
promote differentiation (Milhem, et al 2004). In addition, this effect has been reported to be
maintained by transcriptional reprogramming of HSCs through both acetylation of histone
and DNA demethylation. It is important to point out that the addition of TSA alone to the
cultured cells led to more limited expansion of primitive HSCs cell number but not function,
whereas the addition of 5AzaD alone preserved and function of primitive human HSCs, an
effect  significantly  increased  by  the  combination  of  TSA/5AzaD.  VPA  is  a  different
chromatin modeling agent from TSA as well as 5AzaD with respect to structure and function.
However, it has capacity to induce both histone acetylation and DNA hypomethylation and
increase repopulation efficiencies of murine HSCs, suggesting its effect on early HSCs due to
both acetylation of histone and demetylation of DNA. However, one should be careful in
comparing the results of the studies on humans and mice. Therefore, it might be useful to
investigate the effect of VPA on primitive HSCs by NOD-SCID assay for human marrow
repopulating cells.
Furthermore, another study (De Croce, et al 2005) assesing the effect of VPA on human HSC
in the presence of early cytokines indicated that VPA enhanced significantly the cytokine-
induced ex vivo expansion of early compartment of human HSCs and increased histone H4
acetylation  leves  at  specific  regulatory  sites  on hoxb4 in human HSC, indicating the
potentiality of novel epigenetic approaches to modify HSC fate in vitro. However, self-
renewal and/or engraftment of long-term repopulating stem cells in animal models were not
analyzed.
Moreover, it is important to point out that present study as well as other recent studies
discussed in this report support the recent hypothesis (Akashi et al) that maintenance of self-
renewal and multipotential capability requires that HSCs express a broad set of transcription
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fate decision are likely to be alterable and under the contol of chromatin modeling program,
which guides transcriptinonal accesssibilty for each hematopoietic stage.
In the present study; thus, a potent HDI VPA, known to induce differentiation
 or apoptosis in
leukemic blasts, has been demonstrated to stimulate the proliferation and self-renewal of
primitive  HSCs  through  most  likely  both  inhibition  of  GSK3β  and  transcriptional
reprogramming of HSCs
This novel effect of VPA on HSCs may have important therapeutic consequences. Among the
various forms of leukemia, the myeloid diseases have been best characterized with regard to a
stem cell origin. Interestingly, acute myelogenous leukemia (AML) is known to display
marked clinical heterogeneity (types M0-M7) according to the French-American-British
(FAB) classification system. However, at the stem cell level, there appears to be substantial
conservation. A clone of leukemia cells seems to be organized as a hierarchy that originates
from a stem cell pool like normal hematopoietic system (Bonnet and Dick, 1997). Conversely,
LSCs could also be more restricted progenitor which would have first to reacquire self-
renewal capability. But, it is clear that leukemic cells require
  self-renewal capability to
propagate the disease (Passegue, et al 2003). This idea suggests similarities in the molecular
regulation of both normal and AML stem cells.
Anti-leukemia treatments have historically sought to eliminate proliferating cells. But like
normal HSCs, leukemic stem cells are dormant and rarely proliferate, therefore, resistant to
such therapies. Valproic acid induced entry of quiescent hematopoietic
 and leukemic stem
cells into the cell cycle could render them
 more susceptible to conventional chemotherapy,
resulting either
 in a prolonged aplasia (bone marrow failure to produce blood cells after
chemotherapy) due to a higher efficiency of the therapy
 or in a shortened aplasia owing to the
enforced proliferation
 of the normal hematopoiesis. The recent clinical data indicate that
exposure to valproic acid increases the response to
 chemotherapeutic agents (Bug, et al.
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Therefore, the data reported in this study suggest reconsideration of the role of HDIs
 from
desired  differentiation  inducers  to  a  coadjuvant  factors
 for  increasing  the  response  to
conventional therapy in AML. However, more extensive knowledge of the effect of chromatin
modeling events or players on HSCs is required. As there are many connections between
normal and malignant stem cells, these studies will provide a much clearer picture of the
leukemic stem cells and thus help to increase the efficiency of not only existing therapeutic
approaches but also to initiate novel, biology-based, rational therapeutic approaches for the
treatment of leukemia.Summary                                                                                                                                90
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6 Summary
Acute myeloid leukemia (AML) is characterized by the accumulation of a large number of
abnormal, immature blast cells. Recently, histone deacetylase inhibitors (HDIs), which
regulate transcription through modification of chromatin structure, received considerable
interest on the ground of their ability to overcome the differentiation block in these leukemic
blasts regardless of the primary genetic alteration, an effect achieved either alone or in
combination
 with differentiating agents, such as all-trans retinoic acid (t-RA).
Valproic acid (VPA), a potent HDI, is now under clinical evaluation owing to its potent
differentiation effect on transformed hematopoietic progenitor cells and leukemic blasts from
AML patients. Conversely, in a clinical study by Bug et al., the favorable effects of the
combination treatment with t-RA/VPA in advanced acute myeloid
 leukemia patients were
reported to be most likely due to an enhancement of nonleukemic myelopoiesis
 and the
suppression of malignant hematopoiesis rather than enforced
 differentiation of the leukemic
cells. Moreover, there is evidence that the wide-open chromatin structure required for HSCs
multipotentiality  and  the  lineage  potential  is  hierarchically  controlled  during  early
hematopoiesis most likely through the control of chromatin modeling program. Consistent
with this hypothesis, VPA has been reported to enhance early acting cytokine effect on the
maintenance and expansion of primitive normal human HSCs at least in vitro. Hence, the
effect of chromatin modeling by VPA on HSCs was investigated with regard to proliferation,
differentiation as well as self-renewal in order to evaluate potential for clinical usage of HDIs
in acute myeloid leukemia (AML) therapy.
According to the data observed in the present study, VPA increases both proliferation and
self-renewal of HSCs as shown by immunophenotypical features, both in vivo and in vitro
functional HSC characteristics as well as cell cycle and gene expression analyses.
It is clearly indicated that VPA enhanced the stem cell phenotype and/or increased the number
of human HSCs isolated from both adult bone marrow (BM) and umbilical cord blood (CB)
rather than differentiated cells either in the presence of early acting cytokines or an external
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Furthermore, VPA enhances proliferation and self-renewal of murine HSCs as demonstrated
by the increase in CFU, the percentage of stem cell marker-expressing cells as well as the
replating efficiency of cultured murine HSCs with constant CFU in vitro. The enhancing
effect of VPA on the replating efficiency of HSCs due to their self-renewal was also
confirmed in vivo by an increase in the colony forming unit spleen on day 12 (CFU-S D12)
and competitive repopulation efficiency of VPA-treated HSCs.
Based on the cell cycle analysis, valproic acid accelerates murine HSC cell cycle progression
from G1 phase to S phase as indicated by the increase in the percentage of cells in S phase
and the concomitant decrease in those in G1 phase. In addition, this process is accompanied
by a down-regulation of p21
cip-1/waf-1 as demonstrated in both human and murine HSCs.
On the molecular level, VPA inhibits GSK3ß
 by phosphorylation on Ser9 accompanied by an
activation of the
 Wnt signaling pathway in HSCs. Moreover, HoxB4, a transcription factor as
well as a target gene of Wnt signaling, is up-regulated upon exposure to VPA in human and
murine HScs. Both, the Wnt signaling pathway and HoxB4 are known to directly stimulate
the proliferation of HSC and to expand the HSC pool.
To  sum  up,  valproic  acid,  a  potent  histone  deacetylase  inhibitor  known  to  induce
differentiation
 and/or apoptosis in leukemic blasts, stimulates the proliferation and self-
renewal of hematopoietic stem cells. Therefore, the data reported in this study suggest to
reconsider the role of histone deacetylase inhibitors from a desired differentiation inducer to a
coadjuvant  factor
 for increasing the response to conventional therapy in acute myeloid
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7 Zusammenfassung
Akute myeloische Leukämie (AML) ist gekennzeichnet durch die Akkumulation einer großen
Zahl  abnormaler  Zellen,  die  nicht  in  funktionelle  Granulozyten  oder  Monozyten
differenzieren können. Die überwiegende Mehrheit der AML-Patienten ist über 60 Jahre alt.
Standardtherapie ist eine dosisintensive Chemotherapie mit dem Ziel einer kompletten
Remission, gefolgt von unterschiedlichen Formen einer Postremissionstherapie. Ein kleiner
Teil der Patienten kann mit diesem Therapieansatz geheilt werden. Die meisten Patienten
sterben jedoch innerhalb der ersten 2 Jahre aufgrund einer refraktären oder rezidivierten
Erkrankung oder an Therapiefolgen.
Verschiedene genetische Änderungen resultieren in einem gemeinsamen Muster deregulierter
Genexpression,  welches  zu  einem  Differenzierungsblock  führt,  der  die  myeloide
Leukämogenese fördert. Zusätzlich zur Induktion des leukämischen Phänotyps zeigen sich bei
AML aberrante Chromatinremodellierung und Interaktionen von AML-Fusionsproteinen mit
Corepressor/Histon-Deacetylase-Komplexen.  Man  nimmt  an,  dass  Histon-Deacetylasen
(HDACs) durch Erniedrigung des Acetylierungslevels der core-Histone unter anderem auch
Gene reprimieren, die eine Rolle in Differenzierung und Zellzykluskontrolle spielen. Die
starke Toxizität und die limitierte Effizienz heutiger chemotherapeutischer Strategien, sowie
die  der  AML  zugrunde  liegenden  biologischen  Mechanismen,  haben  zur  Entwicklung
alternativer Therapieansätze geführt, wie z.B. der Differenzierungs-induzierenden Therapie
mit Histon-Deacetylase-Inhibitoren (HDIs). HDIs sind Substanzen, die die Hyperacetylierung
von  core-Histonen  induzieren  können  und  somit  zur  Verringerung  des  Chromatin-
Kondensationsgrades  führen.  Dies  wiederum  erhöht  die  Zugänglichkeit  der  DNA  für
Transkriptionsfaktoren und aktiviert somit Genexpression. Es ist gezeigt worden, dass HDIs
wie  z.B.  Trichostatin  A  (TSA)  oder  Valproinsäure  (VPA)  entweder  alleine  oder  in
Kombination mit Differenzierungs-induzierenden Agenzien wie all-trans-Retinsäure (t-RA),
den Differenzierungsblock in leukämischen Blasten unabhängig von der primären genetischen
Veränderung überwinden können.Zusammenfassung                                                                                                                 93
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VPA  (2-Propyl-Pentansäure)  ist  eine  kurzkettige,  verzweigte  Fettsäure  mit  günstigen
pharmakokinetischen Eigenschaften, welche schon seit Jahrzehnten in der Behandlung von
Epilepsien eingesetzt wird. Neuere Untersuchungen zeigten, dass Valproinsäure neben ihrer
seit langem genutzten Wirkung auch einen Einfluss auf das Epigenom haben kann, indem sie
Histonacetylierung und DNA-Methylierung induziert. Darüber hinaus befindet sich VPA
aufgrund  seiner  potenten  Differenzierungseffekte  auf  Karzinomzellen,  transformierte
hämatopoetische  Vorläuferzellen  und  leukämische  Blasten  von  AML-Patienten  in  der
klinischen Erprobung.
Auf der anderen Seite wurde in einer klinischen Studie allerdings gezeigt, dass eine VPA/t-
RA-Kombinationstherapie  bei  AML-Patienten  in  fortgeschrittenen  Stadien  zu  einer
erheblichen Reduktion der Zahl an Blasten und einer peripheren Hypergranulozytose führt.
Überdies war es in einem Patienten möglich normale und maligne Hämatopoese anhand des
Vorkommens des Isochromosoms (17)(q10) in den leukämischen Blasten zu unterscheiden.
Während CD34-positive Progenitorzellen zu einem geringen Teil noch dieses Isochromosom
enthielten, hatten reife Granulozyten einen normalen Karyotyp, was nahe legt, dass es nicht
zur forcierten Differenzierung kommt, sondern dass die normale Hämatopoese dominant
gegenüber dem malignen Zellklon ist.
Außerdem wird zur Zeit gemutmaßt, dass eine offene Chromatinstruktur essentiell für die
Multipotenz hämatopoetischer Stammzellen (HSCs) ist und das Differenzierungspotential
während der frühen Hämatopoese hierarchisch kontrolliert wird, sehr wahrscheinlich über
Chromatinmodellierung. In Einklang mit dieser Hypothese führte eine Kombination des
Hydroxamsäure-basierten  Histon-Deacetylase-Inhibitors  Trichostatin  A  mit  DNA-
demethylierenden Agenzien zu einer signifikanten Expansion hämatopoetischer Stammzellen,
welche zur Repopulation immundefizienter Mäuse in der Lage waren. Zudem konnte gezeigt
werden,  dass  Valproinsäure  frühe  Zytokin-Effekte  auf  den  Erhalt  und  die  Expansion
primitiver menschlicher HSCs zumindest in vitro verstärken kann. Daher wurde in der
vorliegenden Arbeit der Effekt von Valproinsäure-induzierter Chromatinmodellierung auf das
Schicksal hämatopoetischer  Stammzellen  untersucht,  um  damit  die  Möglichkeiten  des
Einsatzes von Histon-Deacetylase-Inhibitoren in der AML-Therapie zu evaluieren.Zusammenfassung                                                                                                                 94
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Zur  Bestimmung  der  Effekte  von  Valproinsäure  auf  menschliche  hämatopoetische
Stammzellen in der Gegenwart sehr früh agierender Zytokine sowie in einem externen,
Differenzierung  favorisierenden  Milieu,  wurden  die  Proliferation  und  das
Differenzierungspotential  menschlicher  HSCs  aus  adultem  Knochenmark  und  von
Nabelschnurblutzellen,  welche  einen  höheren  Prozentsatz  an  frühen  HSCs  enthalten,
analysiert.  VPA  verstärkte  den  Stammzell-Phänotyp  und  erhöhte  nicht  die  Zahl  an
differenzierten Zellen, sondern die der Stammzellen, sowohl in den Knochenmarks- als auch
in den Nabelschnurblutzellen.
Für einen Vergleich der Effekte von Valproinsäure mit dem bekannten Verstärkereffekt von
all-trans-Retinsäure (t-RA) auf das Potential von Maus-HSCs zur Koloniebildung wurden die
Untersuchungen auf hämatopoetische Stammzellen der Maus ausgedehnt. Dazu wurde der
Effekt von VPA auf die Replatierungs-Effizienz muriner HSCs in einem Koloniebildungs-
Versuch dem von t-RA gegenübergestellt. VPA verstärkte nicht nur die Koloniebildung,
gemessen als Kolonie-bildende Einheiten (colony forming units, CFU), sondern auch die
Replatierungs-Effizienz bei konstanter CFU, währenddessen t-RA nur letztere beeinflusst.
Außerdem kam es bei VPA-behandelten Zellen nicht zur Differenzierung, was sich an dem
hohen Prozentsatz an Zellen zeigte, welche Stammzell-Marker exprimierten. Dies deutet auf
eine  Erhöhung  sowohl  der  Proliferationsrate, als auch der Selbsterneuerung der VPA-
behandelten hämatopoetischen Stammzellen hin.
Um herauszufinden, ob der in vitro Effekt von Valproinsäure auf Maus-HSCs auch auf einem
erhöhten Selbsterneuerungspotentials beruht, wurde der Einfluss einer VPA-Behandlung auf
die Bildung von Milzkolonien am Tag 12 (colony forming units-spleen, CFU-S D12) und auf
die kompetitive Repopulation als Indikator für primitive hamätopoetische Stammzellen, die
zu einer zumindest vorübergehenden Repopulation eines Wirtstieres in der Lage sind (short
term HSCs, ST-HSCs), untersucht. Ähnlich wie t-RA verstärkt VPA die Selbsterneuerung
von HSCs, messbar anhand der hohen Zahl von CFU-S D12 und einer Splenomegalie. Zudem
erhöhte sich auch die Effizienz in den kompetitiven Repopulationsversuchen, ein Hinweis
darauf, dass VPA einen Einfluss auf primitive hamätopoetische Stammzellen hat.Zusammenfassung                                                                                                                 95
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Ergänzend zu den Analysen zur Proliferation und Selbsterneuerung der Maus-HSCs wurde
auf zellbiologischer Ebene der Zellzyklus-Status und die Expression des Cyclin-abhängigen
Kinase-Inhibitors (cyclin dependent kinase inhibitor, CDKI) p21
cip-1/waf-1 in VPA-behandelten
HSCs analysiert, um den Einfluss auf die Zellzyklusregulation in der hämatopoetischen
Kaskade beurteilen zu können. Von Histon-Deacetylase-Inhibitoren ist bekannt, dass sie einen
Zellzyklusarrest durch die Aktivierung von p21
cip-1/waf-1 induzieren können, worauf es zur
Differenzierung  und/oder  Apoptose  sowohl  von  leukämischen  Blasten,  als  auch  von
Tumorzellen kommt. Überdies gibt es Hinweise darauf, dass p21
cip-1/waf-1 möglicherweise
Stadien-spezifische Funktionen in der frühen Hämatopoese hat. In der vorliegenden Arbeit
wurde gezeigt, dass Valproinsäure, im Gegensatz zu t-RA, die Zellzyklusprogression muriner
HSCs von der G1- in die S-Phase beschleunigt, was sich in einer Erhöhung des Anteils von S-
Phasen-Zellen bei gleichzeitiger Verringerung des Prozentsatzes von Zellen in der G1-Phase
äußerte.
Außerdem führte VPA zu einer Herunterregulation von p21
cip-1/waf-1 in menschlichen und
murinen  hämatopoetischen  Stammzellen.  Diese  Daten  deuten  auf  einen  direkten
Zusammenhang  zwischen  dem  Differenzierungslevel  und  der  Antwort  auf  Histon-
Deacetylase-Inhibitoren hin. So scheinen sehr unreife Zellen mit einer Herunterregulation von
p21
cip-1/waf-1 und Zellzyklusprogression auf VPA zu reagieren, während es in fortgeschrittenen
Differenzierungsstadien zu einer Hochregulation von p21
cip-1/waf-1 und Differenzierung oder
Apoptose kommt.
Es  ist  bekannt,  dass  Wnt-Signale  und  der  Transkriptionsfaktor  HOXB4  direkt  die
Proliferation von hämatopoetischen Stammzellen stimulieren und damit zu einer Expansion
des  Pools  an  HSCs  führen.  Glykogen-Synthase-Kinase 3β  (GSK3β) ist ein negativer
Regulator des Wnt-Signatransduktionswegs, welcher zu Stabilisierung von β-Catenin und
letztendlich zur Selbsterneuerung von HSCs führt. Vor kurzem wurde gezeigt, dass es nach
VPA-Behandlung zur Inhibition von GSK3β durch Phosphorylierung an Serin 9 des Proteins
kommt. Um die molekularen Mechanismus aufzuklären, durch welche Valproinsäure die
Proliferation und Selbsterneuerung von HSCs induzieren, wurde der Effekt von VPA auf die
Expression und Modifikation von GSK3β in menschlichen und murinen HSCs, sowie in KG-
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CD34
+/CD38
–),  untersucht.  VPA  induzierte  die  Inhibiton  von  GSK3β  durch
Phosphorylierung an Serin 9 bei gleichzeitiger Aktivierung des Wnt-Signalweges. Zusätzlich
wurde eine quantitative Analyse der Expression des HoxB4-Gens in HSCs aus Mensch und
Maus durchgeführt. Zum einen ist HoxB4ein Zielgen des Wnt-Signalweges, zum anderen
stellt der von ihm codierte Transkriptionsfaktor ein Schlüsselmolekül in der Regulation von
Selbsterneuerung  und  Proliferation  hämatopoetischer  Stammzellen  dar.  Die
Genexpressionsanalysen zeigten deutlich, dass die Behandlung mit Valproinsäure einer
Erhöhung der HoxB4-RNA Level im Vergleich mit t-RA behandelten und unbehandelten
Zellen führt.
Zusammenfassen  lässt  sich  konstatieren,  dass  der  Histon-Deacetylase-Inhibitor
Valproinsäure, der für die Induktion von Differenzierung und/oder Apoptose in leukämischen
Blasten bekannt war, die Proliferation und Selbsterneuerung hämatopoetischer Stammzellen
stimuliert. Diese Effekte lassen sich wahrscheinlich sowohl auf eine Inhibition von GSK3β in
HSCs,  als  auch  auf  eine  transkriptionelle  Reprogrammierung  dieser  Zellen  durch
Chromatinmodelling zurückführen.
Diese neu beschriebenen Effekte von Valproinsäure auf hämatopoetische Stammzellen
könnten wichtige Konsequenzen für die AML-Therapie haben. Der VPA-induzierte Eintritt
von ruhenden hämatopoetischen und leukämischen Stammzellen in den Zellzyklus könnte
diese empfindlicher gegenüber konventioneller Chemotherapie machen. In der Tat konnte vor
kurzem in einer klinischen Studie gezeigt werden, dass Valproinsäure das Ansprechverhalten
gegenüber einer Chemotherapie verbessert.
Die in der vorliegenden Arbeit erhobenen Daten weisen darauf hin, dass die Rolle von
Histon-Deacetylase-Inhibitoren  in  der  AML-Therapie  überdacht  werden  sollte  und  sie
weniger als Differenzierungs-Induktoren, sondern eher als Coadjuvantien mit dem Potential
zur Verbesserung des Ansprechverhaltens auf konventionelle Chemotherapien gesehen
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Abbreviations
A ALL Acute lymphoblastic leukaemia
AML Acute myeloblastic leukaemia
APL Acute promyelocytic leukaemia
ATP Adenosintriphosphat
B BM Bone marrow
BCR Breakpoint cluster region
Bp Base pair
BrdU Bromodeoxyuridine-Triphosphat (Br-dUTP)
BSA Bovine Serum Albumin
C CB Umbilical Cord Blood
CDKI Cyclin-dependent kinase inhibitor
cDNA Copy DNA
CFU Colony forming unit
CFU-S Colony forming unit spleen
CLL Chronic lymphoblastic leukaemia
Cm Centimeter
CML Chronic myeloblastic leukaemia
CSF Colony stimulating factor
D DEPC Diethylpyrocarbonat
DMEM Dulbecco’s Modified Eagle Medium
DMSO Dimethylsulfoxid
DNA Deoxyribonucleic acid
E E. coli Escherichia coli
ECL Enhanced chemiluminescence
EDTA Ethylendiamin-N,N,N’,N’-Tetra-Acetat
F FAB-classification French-American-British-classification
FACS Fluorescence activated cell sorting
FCS Fetal calf serum
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G GM-CSF Granulocyte-macrophage colony-stimulating factor
G-CSF Granulocyte colony-stimulating factor
Gy Gray
H HDAC Histon deacetylase
HDI Histone deacetylase inhibitor
HSC Hematopoietic stem cell
I IgG Immunoglobulin G
IL-3 Interleukin-3
IL-6 Interleukin-6
IMDM Iscove’s Modified Dulbecco’s Medium
K kDa Kilodalton
L LB-Medium Luria-Bertani-Medium
M M Molarity
µgMicrog ramm
Min Minute
Ml Microliter
µM Micromolar
MNC Mononuclear cell
mRNA Messenger ribonucleic acid
N NgNanog ramm
P PB Peripheral blood
PBS Phosphate-buffered saline
PCR Polymerase-chain reaction
PI Propidiumjodid
PML Promyelocytic leukemia gene
R RARα Retinoic acid receptor alpha
RARE RAR specific regulatory element
RNA Ribonucleic acid
Rpm Rounds per minute
RPMI-Medium Roswell Park Memorial Institute-Medium
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RXR Retinoic X receptor
S Sec Second
Sca-1 Stem cell antigene 1
SCF Stem cell factor
SDS sodium dodecyl sulphate
SDS-PAGE SDS-polyacrylamid gel electrophoresis
T TBS Tris-buffered saline
TBST Tris-buffered saline + Tween 20
TEMED N,N,N’,N’-Tetramethylethylendiamin
t-RA All-trans retinoic acid
Tris Tris-(hidroxymethyl)-Aminoethan
t(15;17) Translocation of chromosome 15 and 17
t(8;21) Translocation of chromosome 8 and 21
t(9;22) Translocation of chromosome 9 and 22
t(12;21) Translocation of chromosome 12 and 21
U U Unit
V V Volt
v/v Volume per volume
VPA Valproic acid
W w/v Weight per volumeCurriculum Vitae
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